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Abstract 
MULTIPLE MYELOMA AND ITS TREATMENT ALTER PERIPHERAL NERVOUS 
SYSTEM STRUCTURE AND FUNCTION  
 
 
Alyssa Katarina Kosturakis, BA 
 
Supervisory Professor: Patrick M. Dougherty, PhD 
 
 
 
         Peripheral neuropathy is among the most deleterious side effects of frontline 
chemotherapeutics used to treat prevalent cancers. Chemotherapy-induced peripheral 
neuropathy (CIPN) refers to the collection of symptoms (e.g. pain, paresthesias and 
dysesthesias) that develop in distal, glabrous (non-hairy) skin of 20 to 100% of 
patients treated with chemotherapy. Peripheral neuropathy negatively impacts quality 
of life in cancer patients and survivors, is refractory to treatment, and is the impetus for 
dose-reduction and/or cessation of chemotherapy, thereby limiting treatment. 
Proteasome inhibitor, bortezomib (Velcade®) is an effective treatment of multiple 
myeloma (MM), but often provokes the development of small fiber, sensory, distal 
neuropathy in patients. MM is caused by malignancy of plasma cells, which indirectly 
compromises multiple organ systems. Therefore, the contribution of underlying 
disease versus chemotherapeutic treatment on the development of sensory deficits in 
MM patients remains unclear. 
        This study determined the incidence of subclinical neuropathy in multiple 
myeloma patients prior to receiving chemotherapy. MM patients underwent 
quantitative sensory testing (QST), which is a non-invasive battery of tests that 
provides information about the function of discrete sensory fiber types. Patients 
exhibited a high incidence (>80%) of one or more subclinical QST deficits, including 
vii 
 
mechanical stimulation, fine tactile discrimination, and warmth detection thresholds, 
compared to healthy volunteers. QST also demonstrated enhanced cold pain, 
sensorimotor deficits, and higher overall neuropathy scores in MM patients. The 
peripheral innervation of the skin was visualized with non-invasive confocal 
microscopy and revealed a reduction in the density of touch receptors (Meissner’s 
corpuscles) that negatively correlated with performance on the Bumps detection task. 
Therefore, MM patients commonly present with sensory and sensorimotor deficits prior 
to undergoing treatment, and these deficits appear to be due to disease-related 
decreases in peripheral innervation density.  
        This study subsequently evaluated the efficacy of minocycline in the prevention of 
treatment-emergent bortezomib-induced peripheral neuropathy in a double-blind, 
placebo-controlled, randomized phase I clinical trial by assessing QST and patient 
reports. The placebo group did not show changes in sensory thresholds after 
bortezomib treatment, making it difficult to assess the impact of minocycline on 
sensory deficits. The minocycline group reported lower rates of tingling that 
approached statistical significance (P=0.11). Although statistical significance was not 
reached in patient reports of symptoms, several limitations inherent in the study design 
and data collection likely impacted the result. Therefore, the use of minocycline to 
prevent chemotherapy-induced peripheral neuropathy warrants further investigation in 
a follow-up trial.  
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1. Introduction 
        Cancer currently affects over 1.6 million people in the United States and by 2030, 
this number is estimated to increase to 2.3 million 1,2. Cancer claims 1 in 4 American 
lives and is the second most common cause of death. In less than 20 years, cancer is 
expected to be the biggest killer of any single disease 3. However, with increasingly-
sensitive tests for detecting cancer and the administration of frontline 
chemotherapeutic agents, the number of cancer survivors is expected to increase 35% 
from 13.7 in 2012 to 18 million by the year 2022 4. Chemotherapeutics are effective in 
stopping the progression of cancer because they are often designed to differentially 
target and eliminate rapidly dividing cancer cells. Despite their advantages in the 
cancer-fighting arena, they are also associated with deleterious side effects (e.g. 
anemia, appetite changes, constipation, diarrhea, nausea, vomiting, neurological 
changes, infection, fluid retention, fatigue, hair loss, infertility, pain and peripheral 
neuropathy) that negatively affect normal cells and structures of the body 5. Given the 
potential longevity of biochemical and cellular changes induced by cancer and 
chemotherapy, cancer survivors will require a life-time of medical monitoring and 
treatment for cancer and/or drug-induced health problems and comorbidities 3. Of the 
adverse effects induced by cancer treatment, 20 to 100% of patients (depending on 
the study design and agent) develop a condition known as chemotherapy-induced 
peripheral neuropathy (CIPN) 6,7. CIPN occurs when peripheral nerves are damaged, 
resulting in abnormal sensory function, and pain or loss of motor control. This 
condition sometimes leads to chemotherapy dose decrease or cessation, thereby 
limiting the efficacy of cancer treatment. The investigations conducted focus on the 
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neuropathy multiple myeloma (MM) patients develop from underlying malignancy as 
well as frontline chemotherapeutic agent, Bortezomib (Velcade ®). The following 
sections provide a review of the peripheral nervous system, neuropathic pain 
conditions, CIPN, MM and treatment agent bortezomib and may be relevant 
background information for the reader.  
1.1. Peripheral Nervous System  
        CIPN is a condition that develops due to insult to the peripheral nervous system 
(PNS). The PNS is the network of nerves and ganglia that reside outside of the brain 
and spinal cord and is divided into the somatic and autonomic nervous systems. The 
autonomic nervous system involuntarily modulates the functioning of the viscera such 
as heart rate, respiration rate, perspiration, digestion, sexual arousal and swallowing. 
The somatic nervous system is comprised of the nerves that relay sensory and motor 
information to and from the central nervous system (CNS). These nerves provide 
communication between the skin, sensory organs, joints and all skeletal muscles. The 
skin is the largest sensory organ of the body and is home to the endings (both free and 
specialized) of primary afferent sensory neurons that transmit stimuli (mechanical, 
thermal, and chemical stimuli) from the environment to the CNS. Primary afferents 
provide the body with tactile, thermal and nociceptive (actual or potential tissue 
damage) information about the external world or the body’s relationship to the external 
world (proprioception) 8. Primary afferents are distinct from other types of neurons in 
the body because they are pseudo-unipolar. Pseudo-unipolar cell bodies are situated 
in between two axons capable of sending information bi-directionally. The axons of 
primary afferent neurons form terminals in the skin and transmit sensory information 
from a designated area called a receptive field 8. Receptive fields of sensory neurons 
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can vary based on the type of neuron or location in the body. Primary afferent sensory 
neurons (including nociceptors) can be classified according to 1. structure and 
conduction velocity, 2. modality specificity, 3. threshold of activation and adaptability, 
4. receptor expression and cell content.   
1.1.1 Structure and Conduction Velocity of Primary Afferents 
        The structure of primary afferent fibers determines function. There are four broad 
classes of primary afferents that have differing axon diameters and myelin thickness, 
which determine properties such as conduction velocity. These classes of fibers are 
Aα-, Aβ-, Aδ- and C-fibers. Aα-fibers are thickly myelinated and are the largest in 
diameter (12-20 µm). Aα-primary afferent sensory neurons are proprioceptors that 
innervate skeletal muscles and provide information about limb and body position in 
space with conduction velocities of 70-170 m·s-1. Aβ-fibers are myelinated primary 
afferent sensory neurons that transmit mechanical information such as light touch. 
These have slightly smaller diameters of 6-12 µm and relatively fast conduction 
velocities (35-75 m·s-1). Aβ-fibers innervate specialized sensory organs with 
characteristic structures allowing detection of the quality (e.g. brief versus long in 
duration) of mechanical stimuli (Section 1.2.6). In addition to sensory neurons that 
convey information about mechanical stimuli, there are two broad classes of 
nociceptors that exist in the skin Aδ- and C-fibers. Aδ-fibers transmit acute or sharp 
pain, are thinly myelinated and have conduction velocities of 5-30 m·s-1. C-fibers 
encoding dull, burning and diffuse pain are unmyelinated and have slow conduction 
velocities (0.5-2 m·s-1) 9. The above characteristics and categories of primary afferent 
neurons are not absolute and are an oversimplification of the true physiology. These 
characteristics in isolation cannot be used to identify whether a fiber is a nociceptor or 
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not without further evidence of encoding noxious stimuli 10. For example, there is 
evidence that a small percentage of Aα- and Aβ-fibers are nociceptive 11.   
1.1.2 Modality Specificity of Primary Afferents  
        The subset of primary afferent neurons responsible for the transmission and 
sensory phenomenon of pain are termed nociceptors. Nocicepters are broadly 
classified into polymodal, thermal, or mechanical categories 12. Polymodal nociceptors 
respond to potentially harmful or harmful mechanical, thermal, and chemical stimuli 
and are the most ubiquitous type of nociceptor in the skin. Thermal nociceptors 
respond to temperatures associated with tissue damage (greater than 45 °C or less 
than 5°C). Mechanical nociceptors respond to harmful or potentially harmful amounts 
of pressure applied to the skin 8. It is believed that these nociceptors work in synergy 
to produce different qualities of pain 12. For example, pain that is sharp in quality (“first” 
pain) and felt acutely is predominately carried by fast-conducting, myelinated Aδ-fibers 
while dull, achy pain (“second” pain) is carried by slow-conducting unmyelinated C-
fibers 13. Mechanically-insensitive afferents (MIAs) have also been identified that 
respond to chemical, but not mechanical stimulation 14. In primates, MIAs make up 
approximately 30% of C-fibers and 48% of Aδ-fibers 14. Other subsets of primary 
afferents have been characterized in the cat, rabbit, and rodent, and are sensitive to 
several modalities or selectively sensitive to different ranges of a certain modality such 
as Mechano-cold (C-MC) afferents and Aδ-cold receptors 15,16. 
1.1.3 Threshold for Activation and Adaptation of Primary Afferents 
        Activation thresholds and adaptation are two other characteristics of sensory 
neurons. The following characteristics mentioned commonly refer to cutaneous 
primary afferents that transmit mechanical stimuli (mechanoreceptors). Low-threshold 
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mechanoreceptors (LTM) respond to low grades of mechanical force (e.g. touch), 
whereas high-threshold mechanoreceptors respond to noxious, or potentially noxious 
mechanical forces 17. Classically, nociceptors (Aδ- and C-fibers) were thought to have 
a high activation threshold, responding only to strong, potentially-damaging stimuli, 
whereas Aβ-fibers were thought to be LTM 18. However, low threshold 
mechanonociceptors and “silent nociceptors” (nociceptors activated by sustained 
nociceptive input rather than immediately following tissue injury) have been identified 
19
. Sensory neurons have also been categorized as slowly or rapidly adapting, based 
on the encoding of stimulus information. Sensory neurons are tuned to differentially 
provide information about the range of magnitude or frequency of the stimuli. Slowly 
adapting afferents generate trains of action potentials (APs) in response to long 
duration stimuli, while rapidly adapting afferents initially fire APs and then go silent 
(Figure 2). Therefore, slowly adapting afferents better encode a maintained stimulus, 
in contrast to rapidly adapting afferents, which encode a stimulus that is rapidly 
changing 9. Types I and II can be used in conjunction with slowly- and rapidly-adapting 
to describe the receptive fields of primary afferents (Figure 2). Type I refers to a small 
area where activation thresholds are low, surrounded by an area where activation 
thresholds become very high. Type II refers to large receptive fields.  
        In addition to conduction velocity, structure, threshold for activation, and modality, 
the expression of transduction molecules and receptors is responsible for the 
properties of individual sensory neurons. 
1.1.4 Receptor Expression and Cell Content of Primary Afferents 
        Primary afferent neurons have heterogeneous cell content and receptor 
expression, which contribute to their modality specificity. For example, the polymodal 
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nociceptive C-fibers can be divided into two classes: peptidergic (expressing peptides 
such as calcitonin gene-related peptide (CGRP) and substance P) and nonpeptidergic 
nociceptors. C-fibers can also be categorized on the basis of receptor expression. 
Peptidergic receptors express TrkA (the high affinity nerve growth factor receptor) 20. 
Non-peptidergic nociceptors express the P2X3 purine receptor, receptors for glial-cell-
derived growth factor and the IB4-lectin-binding site 20. Alternatively, primary afferents 
can be classified by expression of ion channels. For instance, nociceptors express 
voltage-insensitive sodium channels (Nav 1.7 and Nav 1.8) and the non-selective 
cationic channel, transient vanilloid receptor 1 (TRPV1). Nociceptors often express 
multiple-channel types that vary from one afferent to the next and confer different 
properties 10.  
         In summary, primary afferents, and specifically, nociceptors, are heterogeneous 
in their properties, which has made their classification, study and manipulation 
challenging.  
1.1.5 Skin Morphology and Sensory Transduction 
        Sensory transduction through primary afferent fibers begins first with a generator 
potential whereby a stimulus produces excitation of the membrane. Subsets of 
channels located on sensory neurons open in response to stimulation (e.g. 
mechanical, temperature, or chemical) producing graded generator potentials, which 
depolarize the membrane. If the magnitude of the stimulus reaches threshold, an 
action potential is generated proximal to the ending and propagates towards the CNS 
9
. The original stimulus is thus converted into an electrical signal that is transmitted to 
the spinal cord and brain. Stimuli that are greater than the minimum intensity to 
produce an AP are encoded via frequency of action potentials 18.  In most neurons the 
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generation of an AP occurs at the junction between the axon and the cell body, called 
the axon hillock. However, in sensory neurons the generator potential occurs at the 
specialized ending, and when it reaches sufficient magnitude, it initiates an action 
potential just proximal to the sensory ending (Figure 1), which is distal to the cell body 
located in trigeminal ganglia or dorsal root ganglia (DRG).  
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Figure 1 Mechano-Transduction  
Ion channels open in response to mechanical stimulation, producing graded generator 
potentials (receptor potentials). If the magnitude of the stimulus reaches threshold, an 
action potential is generated proximal to the ending and propagates towards the 
central nervous system. 
   
Reprinted from Nature Reviews Neuroscience 12, 139-153, Delmas P, Hao J, Rodat-
Despoix L, Molecular mechanisms of mechanotransduction in mammalian sensory 
neurons. Copyright 2011, reprinted with permission from Nature Reviews 
Neuroscience.  
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        Human skin is composed of epidermis (the most superficial outer layer), 
separated by a collagen basement membrane from the deeper-lying dermis. The 
dermis forms protrusions that are perpendicular to the skin’s surface called dermal 
papillae. Human skin can be hairy or non-hairy (glabrous) 21. Glabrous skin covers the 
palms and soles of the feet and has surface features known as epidermal ridges 21. 
The epidermal ridges on the fingertip are colloquially referred to as fingerprints 9. 
Epidermal ridges are structures that contribute to the pattern of organization of the skin 
22
. Glabrous skin is affected during chemotherapy-induced neuropathy and is the 
subject of the following sections.  
1.1.6 Mechanosensation 
        Glabrous skin is innervated by encapsulated sensory organs (Merkel disks, 
Meissner’s corpuscles, Pacinian corpuscles, and Ruffini endings) as well as free nerve 
endings. Merkel disks are oval structures 10-15 µm in diameter located in the basal 
layer of the epidermis and are slowly adapting, indicating persistent firing in response 
to sustained indentation or pressure on the skin (Figure 2d) 23,24. Merkel disks are low-
threshold mechanoreceptors innervated by Aβ-fibers in a variety of terminal branch 
patterns that is suggestive of the complex discharge rates of slowly adapting type I 
fibers 9. The evidence suggests that Merkel disks act as mechanical transducers by 
releasing glutamate in response to stimulation and generating action potentials in 
axons 24. 
        Ruffini corpuscles are slowly adapting mechanoreceptors identified in hairy 
mammalian skin (Figure 2e). Ruffini corpuscles contain a myelinated Aβ-fiber that 
ends in a club-like structure. Individual fibers emanate from the club-like structure 25. 
Despite their existence in the cat, several experiments suggest that Ruffini corpuscles 
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are absent in glabrous skin of raccoon, primates and humans, therefore, they will not 
be further discussed 9.  
               Meissner’s corpuscles (MCs) are another type of cutaneous 
mechanoreceptor with small receptive fields, located in the dermal papillae that line 
the epidermal ridges in skin (Figure 2b). They are composed of primary afferent 
terminals (multiple Aβ- and at least two types of C-fibers) interdigitated between stacks 
of flattened epithelial (laminar) cells and rapidly adapt to 30 to 50 Hz low frequency, 
“flutter” stimuli 9. Aβ-afferents can innervate more than one MC. Additionally, each 
afferent can innervate different combinations of multiple MCs that are partially 
overlapping 22. C-fiber innervation in MCs is both peptidergic and non-peptidergic. 
Based on optimal frequency for activation and location in the skin, it is thought that 
MCs provide information about an object moving over the skin or conversely, the skin 
moving over an object 26.  
         Pacinian corpuscles are composed of an inner core (formed by specialized 
Schwann cells) and an outer core of lamellae layered like the skin of an onion around 
Aβ-fibers (Figure 2c) 27. This arrangement may allow for incompressible fluid between 
lamellae to press on Aβ-fibers producing a generator potential, and if the stimulus is 
large enough, an action potential. Pacinian corpuscles are low-threshold, rapidly 
adapting structures that are located deeper than Merkel disks and Meissner’s 
corpuscles in the dermis. They have relatively large receptive fields and respond 
optimally to high frequency stimuli such as vibration 28. 
        Aδ- and C-fibers terminate in the dermis and epidermis of the skin as free nerve 
endings where they contribute to nociception as well as the detection of mechanical, 
thermal, and chemical stimuli as previously mentioned (Figure 2g). A subset of C-
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fibers are low-threshold mechanoreceptors that encode light and pleasant touch 
(Figure 2f) 29. Although the presence of Aδ- and C-fibers in the epidermis was initially 
elusive, these fibers can now be easily detected with an antibody against protein-gene 
product 9.5 (PGP 9.5), which is an enzyme located in the cytoplasm of nerves.  
        In summary, glabrous skin is populated with several structures, including sensory 
organs tuned to provide information about specific types of mechanical stimulation and 
free nerve endings conveying polymodal stimuli. 
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Figure 2  Cutaneous Mechanoreceptors 
Glabrous skin contains specialized endings of large myelinated Aβ-fibers (Meissner’s 
corpuscles, Pacinian corpuscles, Merkel cell complexes, and Ruffini corpuscles) that 
encode different qualities of tactile information depending on whether they are rapidly 
adapting (RA) or slowly adapting (SA) and low-threshold (LT) or high-threshold (HT). 
Hairy skin contains guard hairs and down hairs innervated by Aβ- and Aδ-fibers, 
respectively. A subset of C-fibers convey light touch (C-fiber LTM). C-fibers and Aδ- 
fibers also serve as polymodal and mechano-nociceptors.  
 
Reprinted from Nature Reviews Neuroscience 12, 139-153, Delmas P, Hao J, Rodat-
Despoix L, Molecular mechanisms of mechanotransduction in mammalian sensory 
neurons. Copyright 2011, reprinted with permission from Nature Reviews 
Neuroscience.  
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1.1.7 Thermosensation 
        In addition to detecting mechanical stimuli, mammalian skin is also adept at 
sensing temperatures in the range of -10 °C to 60 °C 30. Humans are able to 
qualitatively describe four types of thermal stimuli: painful heat, warmth, painful cold 
and cool 8. Cultured sensory neurons retain sensitivity to temperature, which has 
allowed for electrophysiological investigation of mechanisms of thermosensation 31. 
The non-selective cationic channel, TRPV1, is expressed on sensory neurons and 
allows depolarization in response to heat ≥42 °C or to the chili pepper derivative, 
capsaicin 32. Although it is not the only channel involved in sensing heat, it is 
abundantly clear that TRPV1 plays a key role in the sensation of noxious heat. 
Knockout of TRPV1 in mice causes both a decrease in reaction to noxious heat as 
well as sensitivity to thermal stimulus after tissue injury 33.  Another TRPV family 
member channel, TRPV2, is activated by heat 52 °C and above and is expressed in 
Aδ-nociceptors 34. TRPV3 and TRPV4 are likely to contribute to the perception of 
warmth with activations at 27 to 34 °C and 32 to 39 °C, respectively 30. There is also 
evidence that other TRP channels contribute to the detection of warmth and heat 30. 
        Detection of cool stimuli is mediated through TRPM8, which is predominantly 
expressed in C-fibers and responds to slight decreases (30-32 °C) in skin temperature 
as well as to menthol 35. Although controversial, it is thought that TRPA1 may 
contribute to the perception of extreme cold temperatures. TRPA1 expression may be 
responsible for the sensitivity of a population of in vitro sensory neurons to 
temperatures below 20 °C 36.  
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1.2. Pain, Pain Processing, and Neuropathic Pain 
        Pain is the disagreeable physical or emotional sensation experienced when the 
integrity of tissues and organs of an organism are threatened or damaged 37. Pain is 
subjective, meaning that the same injury can cause different magnitudes of discomfort 
and be experienced for different lengths of time in different individuals. The difficulty in 
quantifying pain in both humans and animals due to a subjective emotional component 
of the sensation is one of many challenges to research in the field. 
1.2.1 Pain Classifications and Definitions   
        Nociceptors are specialized cells; a class of primary afferent sensory neurons 
capable of encoding and transmitting noxious or potentially noxious stimuli to the CNS 
38
. They are composed of an axon located in the periphery, a cell body located in the 
dorsal root ganglion, and central terminals, which synapse on the dorsal horn of the 
spinal cord 39. Nociceptors are located in skin, muscle, joints, and viscera and after 
they are activated by noxious stimuli, they become sensitized either by decreasing 
their threshold for activation, or increasing the magnitude of their response 40. This 
increase in excitability is believed to underlie the hypersensitivity experienced after 
injury. For a brief review of central pain processing see Appendix A.  
        Nociceptive pain functions to protect tissue from further damage by compelling us 
to escape from the harmful stimulus. Three broad classifications of pain exist: 
nociceptive, inflammatory, and pathological pain 41. Nociceptive pain is the high-
intensity, acute pain felt when a noxious stimulus activates nociceptors. Inflammatory 
pain results from activation of the immune system following tissue damage or infection. 
Acute inflammatory pain is provoked by the recruitment of neutrophils, monocytes, and 
macrophages (mature monocytes) to the site of injury that eventually cause swelling, 
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redness, aching, and warmth associated with inflammation 42. Prostaglandins and 
bradykinin are early mediators of inflammatory pain and increase excitability through 
modulation of ion channels on primary afferent sensory neurons. In persistent 
inflammatory states other molecules such as cytokines and growth factors induce 
upregulation of ion channels, receptors, and inflammatory molecules via gene 
transcription 43. Inflammatory pain can be protective to the individual by causing 
sensitization of tissues so that further injury is avoided or maladaptive, such as in 
conditions such as rheumatoid arthritis.  
        Although pain is essential for survival, not all pain is protective. Pathological pain 
can be chronic or intermittent in nature and is due to dysfunction of the nervous 
system. This occurs when pain persists long after initial injury due to dissociation of 
the nociceptive stimulus from the pain-processing machinery. In these cases, pain 
may even spread distally or proximally from the initial site of injury. Dysfunctional pain 
and neuropathic pain are two types of pathological pain. Dysfunctional pain is pain that 
arises in the absence of tissue damage or inflammation. Neuropathic pain is defined 
as “pain arising as a direct consequence of a lesion or disease affecting the 
somatosensory system” 44. Neuropathic pain is debilitating and refractory to 
conventional medications and treatments and consequently, is one of the major 
challenges clinicians face in treating their patients. 
1.2.2 Neuropathic Pain          
       Neuropathic pain is a type of maladaptive pain produced in response to a 
peripheral or CNS injury that persists long after the initial injury and is refractory to 
therapy. Many types of injuries and diseases provoke what is broadly termed 
neuropathic pain. Though neuropathic conditions are similar, underlying disease is 
16 
 
responsible for mechanistic differences and the manifestation of symptoms. For most 
patients, neuropathic pain is caused by focal or multifocal lesions of the PNS, 
generalized lesions of the PNS (polyneuropathies), lesions of the CNS, or complex 
neuropathic disorders 45. Examples of focal or multifocal lesions of the PNS that cause 
neuropathic pain include postherpetic neuralgia, phantom limb pain and diabetic 
mononeuropathy. Generalized PNS lesions that cause neuropathic pain result from 
various conditions, including diabetes mellitus, amyloidosis, alcoholism, HIV-induced 
neuropathy, toxic neuropathy (e.g.: chemotherapy-induced), vitamin B deficiency and 
hereditary sensory neuropathies 45. Lesions of the CNS that cause neuropathic pain 
are spinal cord injury, brain infarction (e.g. of the brainstem and thalamus), 
syringomyelia and neurodegenerative diseases such as multiple sclerosis. Complex 
neuropathic pain disorders that cause neuropathic pain refer to complex regional pain 
syndromes type I and II 45. Therefore, both peripheral and central injury can lead to 
neuropathic pain.  
1.2.3 Peripheral Mechanisms of Neuropathic Pain        
        Peripheral nerve injury can lead to neuropathic pain through a change in the 
properties of primary afferents and how stimuli are encoded. For instance, primary 
afferents become hypersensitive and may fire spontaneously. An upregulation of Nav 
1.7, Nav1.8, Nav 1.9 and potentially, Nav 1.3 sodium channels may induce hyper-
excitability of nociceptors after injury 46. Nav 1.7 opens in response to small 
depolarizations near resting potential; thus modulation of Nav1.7 expression can 
dictate the ease of firing an AP. Nav 1.8 is selectively expressed in DRG neurons and 
opens to allow depolarization in the absence of voltage change. Nav 1.3 is responsible 
for persistent sodium current and is capable of magnifying small depolarizations. 
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Nav1.9 opens at hyperpolarized voltages near resting potential and does not 
inactivate, thereby potentiating depolarization. Changes in receptor expression on 
nociceptors can hence change the firing properties of nociceptors by increasing 
excitability and neurally encoding hypersensitivity. 
        Due to their electrophysiological properties, sodium channels have been linked to 
pain in numerous studies. Clinically, mutations in the gene SCN9A that encodes Nav 
1.7 have been linked to several of the following disorders: inherited erythromelalgia 
and paroxysmal extreme pain disorder patients, display abnormally high pain levels, 
as compared to patients who exhibit congenital insensitivity to pain and are unable to 
feel pain 47-49. Nav 1.8 mutations are associated with small-fiber painful neuropathy 50. 
Pre-clinical studies indicate that Nav 1.9 plays a role in diabetic neuropathic pain and 
inflammatory pain 51. In addition to sodium channels, other channels, such as TRPV1, 
TRPV4 and TRPM8 are up-regulated in injured nociceptors and contribute to the 
development of neuropathic pain 52-54. Other studies have suggested that molecular 
changes in undamaged primary afferents accompany injury and play as important a 
role in the experience of pain 55. 
1.2.4 Central Mechanisms of Neuropathic Pain  
        As mentioned in Appendix A, central sensitization plays a role in pain and 
particularly, in neuropathic pain. The literature implicates a wide array of neurons, ion 
channels, signaling pathways, molecules and non-neuronal cells in central 
sensitization 56. (See Appendix A for further discussion about central pain processing.) 
Damage to peripheral nerves (particularly C-fibers) causes spontaneous activity, which 
in turn alters secondary order neurons in the spinal dorsal horn and results in 
hyperexcitability via diverse molecular changes. This is accomplished through release 
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of the excitatory neurotransmitter, glutamate, as well as peptide neurotransmitters 
from primary afferents and hence, an activation of NMDA receptors on second order 
neurons. Also, an upregulation of N-type calcium channels pre-synaptically and Nav1.3 
channels post-synaptically is believed to underlie this excitability 57,58. In addition to an 
up-regulation in the cellular machinery producing excitability, a decrease in inhibitory 
mechanisms has also been observed in neuropathic pain conditions 59. This could be 
caused by a selective loss of an inhibitory class of neurons, γ-aminobutyric acid 
(GABA) neurons, or a loss of the potassium-chloride exporter (KCC2), which causes 
cells to become more excitable rather than inhibited in the presence of GABA 59,60. 
Research also suggests that changes in descending inhibitory pain pathways may 
lead to the promotion rather than the repression of pain 61. Central changes are not 
limited to the spinal cord and extend into the brain. Technologies such as functional 
magnetic resonance imaging (fMRI), positron emission tomography (PET) and 
magneto-encephalography (MEG) have facilitated detection of pain-related changes in 
the brain, which will not be further discussed here. 
1.2.5 Inflammatory Mechanisms of Neuropathic Pain 
        Recent evidence also points to an involvement of innate immune mechanisms in 
neuropathic pain syndromes, which include an upregulation of diverse inflammatory 
mediators 62. Inflammatory substances may be capable of provoking long-lasting pain 
through inducing neuroplasticity 62. This can be achieved by binding to respective 
receptors, thereby activating downstream signaling molecules capable of entering the 
nucleus and influencing gene transcription.  
        TNF-α is perhaps the most widely studied proinflammatory cytokine in 
neuropathic pain and evokes the release of other anti- and pro-inflammatory cytokines. 
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Animal models of neuropathic pain wherein the nerve is transected or crushed, 
produces demyelination, and degeneration of the distal axon, termed Wallerian 
degeneration 63. In response to this type of nerve injury, Schwann cells, mast cells, 
endothelial cells, and fibroblasts release TNF-α, which in turn, provokes the release of 
other inflammatory mediators. Release of TNF-α is also thought to be responsible for 
activating immune mechanisms through the recruitment of phagocytic macrophages to 
the site of injury 64. In Wallerian degeneration, non-resident macrophages localize to 
the nerve and degrade myelin, contributing to the pain phenotype 65. In addition to 
TNF-α, there is strong evidence of the involvement of many other diverse inflammatory 
mediators and cytokines in pain. Interleukin-6 (IL-6) plays a complex role in pain. IL-6 
is detected in injured primary afferent nerve fibers, DRG, and spinal cord and 
peripheral administration of IL-6 causes increased mechanical hypersensitivity 66. 
However, IL-6 also plays a role in neuronal survival and regeneration in vitro and in 
vivo 66. Interleukin-1 (IL-1) 67 and the chemokine receptors CXCR4, CCR5, CCR4, and 
CCR2 are upregulated following nerve injury and facilitate neuropathic pain conditions 
68
. Upon binding to respective G-protein coupled receptors (GPCRs), chemokines 
potentiate inflammatory and pain states through downstream pathways such as the 
mitogen-activated protein kinase system (MAPK) signaling cascade 68. In addition to 
central neuronal changes, non-neuronal changes also occur. For example, several 
types of glia, including microglia, astrocytes, and satellite glial cells of the DRG are 
activated in chronic pain states 69. Thus, neuropathic pain can be initiated due to 
peripheral or central injury and potentiated by changes in cellular machinery and 
innate immune responses. 
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1.3. Multiple Myeloma Pathophysiology, Diagnosis and Staging 
        Multiple myeloma patients and their sensory deficits prior to treatment as well as 
their development of neuropathic pain post-chemotherapy treatment are the subject of 
this thesis. The disease processes of multiple myeloma will be briefly reviewed here. 
        Multiple myeloma (MM) is a plasma cell neoplasm characterized by uncontrolled 
proliferation of plasma cells accompanied by hypercalcemia, renal dysfunction, anemia 
and bone lesions (called CRAB criteria) 70. Plasma cells are terminally-differentiated B 
lymphocytes that secrete antibodies in response to antigens, thereby protecting the 
individual from infection 71. Plasma cells are located in three areas of the body: spleen, 
lymph nodes, and bone marrow. These locations allow efficient interaction with 
antigens, stimulating release of antibodies, also known as immunoglobulins, into the 
bloodstream. B-cell maturation into plasma cells occurs in the bone marrow and is 
facilitated by contact with growth factors released from reticular stromal cells. 
Chemokines, a family of signaling molecules capable of inducing chemotaxis, are 
released from stromal cells and are critical for plasma cell survival 72. When the 
transformation of B-cells into plasma cells becomes unregulated, plasma cells 
proliferate uncontrollably and overproduce immunoglobulins, which are not adaptive to 
fight infection, but rather, produce the co-morbid conditions present in MM patients.  
     Based on statistics from 2006 to 2010, the number of new cases (adjusted for age) 
of MM is projected to be 5.9 per 100,000 men and 3.4 per 100,000 women 73. 
Diagnostic criteria for MM are based on high numbers of monoclonal plasma cells, 
monoclonal immunoglobulin in serum and/or urine, and bone lesions (apparent in 80% 
of patients at diagnosis). Immunoglobulins (antibodies) are released from plasma cells 
and are Y-shaped. Immunoglobulins have two paratopes located on each arm of the 
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Y-shaped molecules that bind to epitopes on antigens. The Y-structure of an 
immunoglobulin is made up of four polypeptide chains: two identical smaller chains 
(light chains) linked by disulphide bridges to two identical larger polypeptides, called 
heavy chains 74. There are five types of mammalian immunoglobulin heavy chains: α, 
δ, ε, ϒ, µ, which distinguish the immunoglobulin isotypes IgA, IgD, IgE, IgG, and IgM, 
respectively. In mammals, two light chains exist, termed κ and λ. Similar to MM, other 
disorders such as monoclonal gammopathy of undetermined significance (MGUS), 
smoldering multiple myeloma, macroglobulinemia, non-Hodgkin lymphoma, essential 
cryoglobulinemia, heavy chain disease, and idiopathic cold agglutinin disease, also 
present with paraproteinemia, but are all distinct conditions. 
        Paraproteinemia is the overproduction of paraprotein also known as an abnormal 
immunoglobulin light-chain. Patients with MGUS can be distinguished from MM 
patients because they have less than 5% monoclonal plasma cells, but no other CRAB 
symptoms; however, approximately 1% of MGUS cases will progress to MM 75. 
Patients with MGUS or smoldering MM do not require treatment. 
        Individuals diagnosed with MM must exhibit monoclonal plasma cell proliferation 
by bone marrow aspiration and/or bone marrow biopsy. A bone marrow biopsy will 
allow the clinician to assess the immunophenotype of the plasma cells as well as the 
extent of bone marrow infiltration. A bone marrow aspiration is performed to further 
examine the monoclonal cell population with cytogenetics 70. Patient serum and urine 
must also be checked for the presence of monoclonal proteins with serum or urine 
protein electrophoresis. Detection of IgG or IgA proteins is the most common, but 
detection of more than one monoclonal protein is also possible.  
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        Two staging systems for MM are used to quantify severity of disease and predict 
survival: the Durie-Salmon Myeloma Staging System and the International Staging 
System. The Durie-Salmon System (Table 1) assesses tumor cell mass, whereas the 
International Staging System (Table 2) takes into account β2 Microglobulin (β2M), 
which is influenced both by tumor burden and renal function. β2M is the light chain of 
the major histocompatibility complex of the cell membrane and high β2M indicates 
high proliferation of tumor cells 75. The presence and quantification of other factors 
have also been used as prognostic factors. For example, plasmablastic morphology 
and chromosome 13 deletions are associated with poor survival 76,77.  
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STAGE CRITERIA MEASURED MYELOMA 
CELL MASS 
STAGE 1 (low 
cell mass) 
All of the following: 
• Hemoglobin > 10g/dL 
• Serum calcium value normal or 
<10.5mg/dL 
• Bone X-ray: normal bone 
structure (scale 0), or solitary 
bone plasmacytoma only 
• Low M-component production 
rates IgG value <5g/dL; IgA 
value <3g/dL 
• Urine light chain M-component 
electrophoresis <4g/24h 
600 billion/m2 
STAGE II 
(intermediate 
cell mass) 
Neither Stage I or Stage III 600 to 1200 billion in 
whole body 
STAGE III One or more of the following: 
• Hemoglobin <8.5g/dL 
• Advanced lytic bone lesions 
(scale 3) 
• High M-component production 
rates IgG value >7g/dL, IgA 
value >5g/dL 
• Bence Jones protein >12g/24h 
 
>1200 billion 
Subclassification 
(either A or B) 
A: relatively normal renal function 
(serum creatinine value) <2.0 mg/dL 
 
B: abnormal renal function (serum 
creatinine value) >2.0 mg/dL 
 
 
 
Table 1 Durie-Salmon Staging for Multiple Myeloma 78 
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STAGE  CRITERIA 
STAGE I • Serum β2 microglobulin <3.5 mg/L 
• Serum albumin ≥3.5g/dl 
STAGE II       Neither Stage I or Stage III 
STAGE III • Serum β2 microglobulin >5.5 mg/L 
 
Table 2 International Staging System for Multiple Myeloma 79 
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1.4. Treatment of Multiple Myeloma 
 
1.4.1 Bortezomib: Clinical Overview 
        Bortezomib (Millenium Pharmaceuticals Inc. VELCADE®) is a proteasome 
inhibitor first approved in 2003 for the treatment of MM in patients after the failure of 
three previous therapies 80. It was approved following a successful phase 2 open-label, 
nonrandomized trial that showed a 35% complete, partial, or minimal response in MM 
patients that had not improved with other agents 81. 
        Proteasomes breakdown and remove damaged proteins in cells by selectively 
catalyzing the degradation of peptides that have been tagged with a small protein, 
ubiquitin. Bortezomib reversibly inhibits mammalian proteasome 26S, which disrupts 
its ability to cleave and degrade ubiquitin-tagged proteins. The tolerability and efficacy 
of bortezomib are due in part to an increased sensitivity of cancerous plasma cells to 
the drug as opposed to normal cells to the drug. Though bortezomib was designed as 
a proteasome inhibitor, its mechanism for eliminating cancer cells is not fully 
understood 82. One possible mechanism of action of bortezomib is that inhibition of 
proteasomes causes an accumulation of damaged proteins in the cell that interfere 
with cellular function and induce apoptosis 82. Another potential mechanism of the anti-
cancer effects of bortezomib is that through proteasome inhibition it modulates key 
cellular pathways, such as the nuclear factor κB (NF-κB) pathway. NF-κB is a family of 
transcription factors that modulates immune and inflammatory responses. It also plays 
a role in tumorigenesis by inducing growth and proliferation, suppressing apoptosis, 
and enhancing tumor cell invasiveness and metastasis. Inhibitor of nuclear factor κB 
(IκB) is a protein that binds NF-κB in the cytoplasm and inhibits it from travelling to the 
nucleus and initiating transcription of growth factors 82. Normally, proteasome 26S 
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cleaves IκB, however, administration of bortezomib blocks proteasomal degradation of 
IκB. IκB is then able to bind and inhibit NF-κB, thereby blocking cell survival activities 
in tumor cells82. Bortezomib may also induce apoptosis in tumor cells by promoting 
mitochondrial Ca2+ dysregulation, thereby activating pro-apoptotic mediators: caspase 
3, 8, 9 and 12 83. Although bortezomib affects several key cellular pathways, 
interference with these pathways likely has numerous downstream effects, which 
remain to be characterized. Regardless of mechanism, bortezomib shows impressive 
partial and complete response rates when administered as a single agent 81.  
     Bortezomib is typically administered at a dose of 1.3 mg/m2 or 1.0 mg/m2 by 
intravenous bolus or subcutaneously on days 1, 4, 8, and 11 of a 21-day cycle. 
Patients receive multiple cycles depending on individual response rate. The most 
common adverse events associated with bortezomib are fatigue, thrombocytopenia, 
gastrointestinal issues, and sensory neuropathy 81,84-86. In an initial study, 34% of 
patients reported new or worsening symptoms of neuropathy with bortezomib 81. 
Subsequent trials using bortezomib as a single-agent induction therapy for multiple 
myeloma reported treatment-emergent sensory neuropathy in 64% of patients 85. In an 
analysis of two bortezomib phase II studies with 256 enrolled patients, 90 patients 
experienced treatment-emergent neuropathy, 5% of patients discontinued treatment 
due to neuropathic symptoms, and 12% of patients received a dose reduction due to 
peripheral neuropathy 85. Bortezomib-induced neuropathy (BIPN) is typically sensory, 
although motor neuropathy has also been reported 87. The incidence of peripheral 
neuropathy varies depending on the trial, grading scales, and detection methods of 
neuropathy. To increase the efficacy of bortezomib, polymodal therapy has been 
implemented; bortezomib has been combined with several other agents including 
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dexamethasone alone, dexamethasone and thalidomide, prednisone alone, melphalan 
and prednisone and lenalidomide. Richardson et al. reported that multiple therapies do 
not increase the incidence of reported neuropathy 86.  
        Neuropathy is the most clinically relevant side-effect of bortezomib. Due to the 
prevalence of neuropathy, BIPN provokes dose reduction and/or discontinuation of 
therapy. The incidence of neuropathy typically increases as patients receive more 
cycles of chemotherapy and cumulative dose of the drug increases87. Furthermore, the 
most significant risk factor for the development of neuropathy is a previous history of 
neuropathy 88. Fortunately, BIPN may be reversible: 60% of cases return to baseline 
levels of neuropathy within a median of 5.7 months. However, other studies still 
observe neuropathy at a year following treatment 88,89. The etiology and mechanisms 
underlying BIPN are poorly understood. BIPN is debilitating and treatment-limiting and 
requires further investigation in animal models. 
1.4.2 Bortezomib-Induced Neuropathy: Pre-Clinical Studies 
        Animal studies have attempted to characterize the pathophysiology of BIPN. Rats 
treated with bortezomib at a clinically-equivalent dose display neurophysiological and 
histopathological differences compared to control animals. Sensory nerve conduction 
velocity is significantly reduced and the sciatic nerve in these rats exhibits damaged 
Schwann cells and degeneration of myelin, though recovery was observed after 4 
weeks. The dorsal root ganglions (DRGs) of these animals showed increased 
recruitment of satellite cells 90. Bortezomib-treated animals also have an abundance of 
ubiquitin-tagged proteins in DRG neurons and signs of abnormal transcription and 
translation, which likely contributes to sensory neuron dysfunction 91. Taken together, 
these data show that bortezomib damages peripheral nerves and their cell bodies, yet 
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the underlying pathways leading to this destruction are unclear. Despite carefully 
conducted animal studies, the mechanism by which bortezomib induces neuropathy 
remains elusive. 
1.4.3 Other Therapies 
        Thalidomide is another chemotherapeutic agent used to treat MM. Thalidomide 
modulates the immune system to increase natural killer cells and T-cells, inhibiting 
cytokine production and angiogenesis and inducing apoptosis. Potential mechanisms 
of thalidomide-induced neuropathy include the down regulation of tumor necrosis 
factor-α (TNF-α), which induces demyelination and Wallerian degeneration or direct 
damage of the DRG 92. Symptoms include dose-dependent abnormalities in the form 
of distal paresthesias or dysesthesias and possible weakness. Aside from 
chemotherapy, autologous stem-cell therapy is usually considered as an option for the 
treatment of MM and may prolong life if a complete response is attained 93. The 
severity of neuropathy induced by chemotherapeutic agents in individual patients 
dictates the future dose that can be administered. In order to quantify neuropathy, 
several grading scales have been implemented. 
1.4.4 Overview CIPN Symptoms and Grading Scales 
        Primary afferent neurons and their cell bodies located in the DRG are particularly 
vulnerable to the toxic effects of chemotherapy because they do not have a protective 
blood-brain barrier like the CNS. Without the blood-brain barrier, substances in the 
blood can freely exchange across the walls of DRG and affect primary afferents 92. In 
cancer patients this produces an array of sensory disturbances (e.g. numbness, 
tingling, burning, or dysesthesias) broadly known as chemotherapy-induced peripheral 
neuropathy (CIPN) that affect the hands and feet in a glove and stocking distribution 
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94
. Patients typically present with symptoms consistent with CIPN weeks or months 
after beginning chemotherapy treatment. Several chemotherapies are notorious for 
causing CIPN, however the presentation and onset of symptoms varies depending on 
the drug, perhaps due to mechanistic differences. CIPN is generally thought to 
improve after chemotherapy treatment has ended; however, the platin family of 
compounds (e.g. oxaliplatin, carboplatin and cisplatin) is known to cause worsening of 
symptoms after treatment has been stopped (a phenomenon known as “coasting”) 92. 
Bortezomib-treated patients most commonly describe their sensory symptoms as 
tingling (paresthesia), hypersensitivity (hyperesthesia), numbness (hypoesthesia), 
abnormal sense of touch (dysesthesia), burning, or pain and their motor symptoms as 
weakness 95. Although much less common, some chemotherapies such as 
bortezomib, may also affect the autonomic nervous system causing orthostatic 
hypotension, sex organ dysfunction and constipation. For a complete discussion of 
different chemotherapeutics, the potential mechanisms by which they induce 
neuropathy, and the quality of neuropathic symptoms induced, see review articles 
92,96,97
.  
        CIPN is challenging to quantify because of the subjectivity of patient and provider 
reports. Hence several grading systems have been developed in an effort to increase 
objectivity. Historically, three different grading scales of peripheral neuropathy have 
been implemented that categorize neuropathy numerically from Grade 0 to Grade 4. 
These include the World Health Organization (WHO) Common Toxicity Criteria for 
Peripheral Neuropathy, National Cancer Institute (NCI) Common Toxicity Criteria, and 
the Eastern Cooperative Oncology Group (ECOG) Grading Scale for CIPN 98. 
According to the WHO rating scale, a Grade 0 corresponds to no symptoms of 
30 
 
neuropathy, Grade 1 corresponds to paresthesias (a tingling, tickling or prickling 
sensation) and/or decreased tendon reflexes, Grade 2 corresponds  to severe 
paresthesias and/or mild weakness, Grade 3 corresponds to intolerable paresthesias 
and/or marked motor loss and Grade 4 corresponds to paralysis. NCI and ECOG 
ratings make slight modifications to the WHO rating system. The Total Neuropathy 
Score (TNS) is slightly different in that it rates patients with a cumulative score ranging 
from 0 to 32 based on deep tendon reflexes, pin sensation, vibration sense, nerve 
conduction, and subjective self-report of symptoms from the patient 99.   
        Another sensitive, yet non-invasive method of assessing the extent of neuropathy 
is quantitative sensory testing (QST). QST is a battery of testing administered to 
patients that measures sensory function in several different modalities and assesses 
the function of discrete fiber types. Touch detection thresholds measure Aβ-function, 
temperature thresholds measure function of different populations of Aδ- and C-fibers, 
and sharp detection thresholds measure Aδ-fiber function.  A 2010 study using QST 
on 1236 neuropathic pain patients in a multi-center study found both loss and gain of 
sensory function in patients as compared to healthy controls as well as a high degree 
of heterogeneity between patients in the modalities tested 100.  This emphasizes the 
complex array of sensory phenotypes attributable to neuropathic pain syndromes that 
can be differentiated by testing discrete fiber types using QST.  
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1.5. Hypothesis and Specific Aims 
        Peripheral neuropathy as a consequence of chemotherapy is a common cause of 
dose reduction or discontinuation of therapy in cancer patients, thereby limiting 
treatment and negatively impacting survival. In both human and animal models, 
treatment with chemotherapeutics is associated with the development of sensory 
neuropathy and a distal loss of peripheral nerve fibers in glabrous skin 6. However, it is 
unclear whether pre-existing subclinical deficits predispose patients to developing 
chemotherapy-induced peripheral neuropathy and whether pre-clinical therapies 
utilized in clinical trials will successfully treat CIPN. These studies address the 
following hypotheses: 
 
Hypothesis 1: Multiple myeloma patients exhibit decreases in peripheral innervation 
and sensory changes that can be quantified prior to chemotherapy treatment. 
Specific Aim 1.1: Use QST to compare sensory thresholds of multiple myeloma 
patients to age-and-sex matched healthy volunteers.  
Rationale: Colorectal cancer patients prior to induction therapy display 
sensory deficits 153. Ten percent of MM patients present with overt 
clinical neuropathy prior to chemotherapy treatment.  Sensory thresholds 
of MM patients that are different from those of healthy volunteers may 
indicate deficits in the fiber types mediating those modalities. Sub-types 
of fibers with subclinical deficits may be particularly vulnerable to the 
effects of bortezomib. A recently published study suggests that pre-
existing sensory deficits in MM patients are associated with patient 
reports of pain and numbness during treatment 107.  In addition, research 
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suggests that pre-existing neuropathy puts patients at risk for developing 
treatment-emergent neuropathy. 
Specific Aim 1.2: Determine if MM patients exhibit decreases in peripheral 
innervation. Correlate densities of touch receptors (Meissner’s corpuscles) to 
performance on fine tactile discrimination tasks in MM patients and volunteers 
using non-invasive confocal microscopy .   
Rationale: Pre-clinical studies in animals and biopsies in patients indicate that 
sensory neuropathy is and neuropathic-like symptoms are associated with a 
dearth of nerve fibers in distal glabrous skin. 
 
        In addition to subclinical deficits likely caused by disease-related processes, 
studies demonstrate that chemotherapy administration induces or exacerbates 
sensory deficits. The development and application of preventative treatments would be 
useful to avoid this detrimental and dose-limiting side effect. Minocycline is a 
tetracycline antibiotic with neuroprotective properties that reduces hypersensitivity and 
spares primary afferent fibers in rodent models of CIPN.  
 
Hypothesis 2: Oral minocycline administered with the chemotherapeutic agent, 
bortezomib, will prevent sensory neuropathy induced by bortezomib and decrease 
patient-reported outcomes of neuropathy.  
Specific Aim 2.1: Assess the efficacy of 200 mg/day oral minocycline HCL in 
preventing bortezomib-induced neuropathic pain in multiple myeloma patients by 
measuring sensory thresholds using QST and assessing patient reports of 
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tingling and numbness in a randomized, double-blind placebo-controlled, clinical 
trial.  
Rationale: Minocycline has neuroprotective properties in preclinical 
studies investigating both spinal cord injury-induced and chemotherapy-
induced neuropathic pain.  
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2.  Subclinical peripheral neuropathy in multiple myeloma patients prior to 
chemotherapy is correlated with decreased fingertip innervation density 
 
Chapter 2 is adapted from the publication Kosturakis et al., Subclinical peripheral 
neuropathy in multiple myeloma patients prior to chemotherapy is correlated with 
decreased fingertip innervation density, Journal of Clinical Oncology (Accepted). 
 
2.1. Introduction 
       The goal of this study was to quantify sensory deficits MM patients exhibit prior to 
receiving chemotherapy to address Hypothesis 1 of this thesis.  
     MM patients typically seek care with signs of renal insufficiency, anemia and bone 
lesions 101. Bone lesions occur due to bone resorption and include lytic abnormalities 
or diffuse osteopenia, both of which lead to increased calcium in extracellular fluid and 
may cause hypercalcemia. Renal failure can occur due to non-paraprotein-related 
causes (e.g., hypercalcemia, nephrotoxic drugs, dehydration, hyperviscosity, and 
myeloma cell infiltration) or paraprotein-related causes (e.g., cast nephropathy, 
amyloidosis, light chain deposit disease or Fanconi syndrome). Anemia in MM patients 
is usually caused by treatment with chemotherapeutics, deficient production of 
erythropoietin, and tumor infiltration of the bone marrow.  
        Overt neurological complications may also occur from tumor invasion into the 
vertebral space that compresses the spinal cord, cranial nerves or nerve roots, 
intracranial invasion of tumor and metabolic derangements 102,103. Clinically significant 
peripheral neuropathy without clear etiology prior to treatment is reported in 5 to 20% 
of patients 89,102,104,105. The incidence of CIPN affects approximately 70% of patients, 
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depending on the therapeutic agent 104,105. In fact, the development of treatment-
emergent peripheral neuropathy is the most common cause of dose reduction or 
discontinuation of chemotherapy, potentially impacting survival 86,106. The proteasome 
inhibitor bortezomib (Velcade®) is a common treatment for MM and is associated with 
high rates of peripheral neuropathy that may become chronic and refractory to 
treatment 89,105.  
Given the potential profound impact of neurological complications on disease 
treatment and quality of life, interest has centered on identifying means to avoid the 
occurrence of treatment-related neuropathy in MM patients. QST are a series of non-
invasive measures capable of detecting deficiencies in sensory nerve fiber function. In 
one recently published study, the presence of subclinical sensory deficits in MM 
patients was suggested as predictive of the development of CIPN 107. While patients 
with pre-treatment impairments in sharpness detection (a test assessing Aδ-fiber 
function) were at decreased risk for developing CIPN, baseline impairments in warmth 
detection (a test assessing C-fiber function), were associated with more severe pain 
and numbness after chemotherapy treatment 107.  
Biopsies collected from glabrous skin sites in patients treated with 
chemotherapy show decreases in peripheral innervation, including loss of both 
intraepidemal nerve fibers and Meissner’s corpuscles (MCs) 89.  MCs are rapidly 
adapting cutaneous receptors that detect tactile stimuli moving at frequencies of 30 to 
50 Hz 9. This sensation can be described as “flutter.” Non-invasive in vivo confocal 
microscopy is a novel imaging technique for visualizing the epidermis and superficial 
dermis that allows clear identification of MCs within dermal papillae. MC density 
assessed by in vivo confocal microscopy is well correlated to MC density assessed by 
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skin biopsy 108. The goals of this study were to quantify the sensory changes in MM 
patients prior to chemotherapy treatment, thereby determining the prevalence of 
subclinical peripheral neuropathy and to correlate impairments in touch thresholds with 
decreased peripheral innervation density assessed with in vivo laser reflectance 
confocal microscopy. 
 
2.2. Subjects and Methods 
2.2.1 Patients and Volunteers 
        Twenty-seven patients with no previous symptoms, complaints of peripheral 
neuropathy or clear risk factors for neuropathy were recruited into this study through 
the Multiple Myeloma Clinic at The University of Texas MD Anderson Cancer Center. 
A group of 30 age- and sex-matched healthy volunteers recruited from the institution 
staff provided comparative data. All subjects provided informed consent to participate 
in the research protocols that had been reviewed and approved by the Institutional 
Review Board of the MD Anderson Cancer Center.  
2.2.2 Quantitative Sensory Analysis 
Quantitative sensory analysis was performed as previously described 89,108,109. Based 
on the distribution of sensory disturbances that have been documented in CIPN 89,109, 
three areas, the fingertip, thenar eminence (palm) and volar surface of the forearm 
(forearm), were selected for sensory testing. The dermatomes that correspond to the 
fingertip, thenar eminence and volar forearm are C6, C6, and either C6 or C8, 
respectively 110. 
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2.2.3 Touch Detection Thresholds and Grooved Pegboard Test 
Touch detection thresholds were determined using von Frey monofilaments 
(Semmes-Weinstein) (Figure 3) in an up/down manner 89,109. Starting with a bending 
force of 0.02 grams, each filament was applied to the skin for approximately 1 second 
in each of the three test sites mentioned above. During this test, subjects were 
instructed to close their eyes or look away so that they did not see the application of 
the filament. If the subject failed to detect the stimulus, the next higher force was 
applied to the same location. When the subject detected the presence of the stimulus, 
the next lower force was administered. This procedure continued until the same 
filament was detected for three applications, and the associated force was considered 
the touch detection threshold. 
To assess fine touch discrimination, a second method based on the detection of 
minute elevations (bumps detection) on a smooth surface was employed 89,111. The 
bumps device consists of three etched glass plates (11.5 cm x 15 cm), each of which 
contains twelve 1.5 x 1.5 inch squares (Figure 4). Within each square are 5 flat circles, 
each of a different color. Located over one of the circles within each square is a bump 
that is 550 µm in diameter. Bumps on plate 1 vary from 2.5 to 8.0 µm in height, bumps 
on plate 2 vary from 8.5 to 14.0µm in height, and bumps on plate 3 range from 14.5 to 
26 µm in height. Participants began each session using bumps that ranged from 8.5 to 
14 µm. Subjects were instructed to use the index finger of the dominant hand to 
explore the five circles within each square. Patients were unable to see the location of 
the bump and reported to the examiner which color they perceived the bump to be 
located on. If participants could correctly identify the location of bumps on plate 2, they 
progressed to plate 1 (2.5 to 8 um). Patients unable to detect the location of bumps on 
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plate 2 were presented with plate 3 (14.5 to 26um). The Bumps detection threshold 
was determined to be the smallest bump correctly identified in sequence to the next 
two higher bumps 111. 
 
 
  
 Figure 3 Touch Detection Assessed With Von Frey Monofilaments
Monofilaments based on the Semmes
against the skin in sequence (from smallest to 
approximately logarithmic scale of actual force and a linear scale of perceived 
intensity.  
 
 
 
Figure 4 Fine Tactile Discrimination Asses
A bump of known size ranging from 2.5 to 26 um 
circles in each square. Subjects reported the color that corresponded to the location of 
the bump.  
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        Manual dexterity was assessed with the grooved pegboard test (Figure 5) 112. 
Patients were instructed to fill a 5 × 5 slotted pegboard in an ordered fashion, either 
across rows or down columns. The time a subject took to complete the board was 
measured for both dominant and non-dominant hands. A faster time indicated greater 
dexterity 112. 
2.2.4 Sharpness Detection Threshold 
The ability to detect sharpness was determined using weighted needle devices 
of 8, 10, 16, 20, 30, 32, 64, and 128g (Figure 6) 113. Each stimulus was applied for 1 
second in ascending order using a modified Marstock method 114. The subjects were 
instructed to state whether the sensation produced by each stimulus was that of touch, 
pressure, sharpness, or pain. The sharpness detection threshold was the weight 
corresponding to the sensation of ‘‘sharp’’ or ‘‘painful.’’ Sharpness was measured in 
three separate trials separated by an average interval of 30 to 90 seconds. The 
average of three trials was the recorded sharpness detection threshold. 
 
 
 
 
 
 
 
Figure 5 Manual Dexterity Assessed with Grooved Pegboard Test 
A grooved pegboard with irregularly shaped slots oriented at different angles and 
pegs. 
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Figure 6 Weighted, Blunted Needle Assessed Sharpness Detection  
A blunted needle and attached weight were inserted into a plastic tube. The needle 
was applied to the test site and freely moved in the barrel of the plastic tube so that the 
associated weight was applied. Patients were instructed to report whether they 
perceived touch, pressure, sharp or pain. End points for sharpness detection were 
reports of pain or sharp.  
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2.2.5 Heat and Cold Detection Thresholds 
  Warmth detection and heat pain threshold were determined by applying heat 
stimuli to the testing site with a 3.6 by 3.6-cm Peltier probe (Figure 7) 89,109. The 
baseline temperature of the probe was set at 32°C and the temperature increased at a 
rate of 0.30°C/second. Subjects signaled when the probe was first perceived as warm 
and then, painful. The trial was subsequently terminated and the probe returned to 
baseline temperature. The final warmth detection and heat pain threshold for each site 
was defined as the mean of three trials that were separated by an average of 30 to 90 
seconds. If a subject failed to perceive warmth or heat pain, the cutoff temperature of 
52°C was recorded as the default.  
        The threshold to detect cooling of the skin (cool threshold) and then cold pain 
(cold threshold) was determined as described above, except that the temperature 
decreased at a rate of 0.50°C per second. If a subject failed to perceive cold pain, the 
cutoff of 3°C was recorded as the default value. 
2.2.6 Skin Temperature 
Skin temperature was measured using a radiometer placed gently against the skin for 
approximately 2 seconds (Figure 8).  
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Figure 7 Peltier Thermode Probe Assessed Temperature Thresholds 
A thermode was applied to the testing site and increased or decreased in temperature 
to assess warm detection, heat pain, cool detection, and cold pain.  
 
 
. 
 
Figure 8 Skin Temperature Radiometer 
Skin temperature at the testing sites was assessed using a radiometer 
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2.2.7 Imaging and Meissner’s Corpuscle Quantification 
        In vivo confocal imaging was performed on the skin of 12 patients and 10 healthy 
controls using Lucid Vivascope 1500 as previously described (Figure 9) 108. The 
microscope was centered on the tip of the fifth digit over a plastic ring and produced 
an image with a 2.0 mm by 2.0 mm field of view. Skin architecture was assessed using 
a stack of four images with a vertical resolution of 3 to 5 µm at different depths (z 
plane = 20 µm). MCs were quantified at the depth that was most easily visualized by a 
research assistant blinded to the study group. Images that were 4.0 mm2 were divided 
into four quadrants and MCs were quantified on one randomly chosen quadrant.  
Meissner’s corpuscles were identified as round light-colored structures 40 to 60 µm in 
diameter located in dermal papillae as previously described 108. 
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Figure 9 Lucid Vivascope 1500 Non-Invasive Confocal Scanner  
The lens was attached to the site of interest and the non-invasive confocal scanner 
obtained a series of images of different layers of skin. The scanner produced a stack 
of four 2.0 mm x 2.0 mm images taken at depths that varied by 20 µm. The density of 
the touch receptors, Meissner’s corpuscles, were visualized as round, light colored 
structures and quantified on one of the images.  
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2.2.8 Statistical Analysis 
        Comparisons of sensory and sensorimotor thresholds were performed between 
volunteers and patients by first, evaluating for normality using the Shapiro-Wilk test 
and then, using the non-parametric Wilcoxon signed-rank test. Results are reported as 
mean ± standard error of the mean. Correlations were performed with the non-
parametric Spearman’s Rank-Order correlation.  For every comparison, P<0.05 was 
considered significant. 
 
2.3. Results 
2.3.1 Study group 
Patient characteristics are presented in Table 3. None of the patients had a 
history of chemotherapy treatment, AIDS, diabetes or irradiation exposure that might 
have contributed to the development of neuropathy. All QSTs on patients were 
collected before chemotherapy had been initiated. Healthy volunteers had no 
exposure to equipment or testing procedures prior to undergoing QST. QST and scans 
were collected by a study coordinator who did not participate in the data analysis.  
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Patient demographics (n=27)       
Characteristic 
    
n 
  
% 
Age-years, mean (SD)    
60.4  
(9.7)   
Gender       
     Male    13  48.1 
     Female    14  51.9 
Race       
     White    20  74.1 
     Black    5  18.5 
     Hispanic    2  7.4 
International Staging System      
     Stage I    11  40.7 
     Stage II    10  37.0 
     Stage III    6  22.3 
Amyloidosis       
     Yes    3  11.1 
     No       24   88.9 
SD= Standard Deviation     
 
Table 3 Patient Demographics 
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2.3.2 Touch Detection Thresholds and Grooved Pegboard Times 
       Touch detection thresholds, a gauge of Aβ-fiber function 115-117 were obtained 
using von Frey monofilaments. Touch detection was higher (implying impairment) at 
the thenar eminence and the volar forearm, but not the fingertip, in the MM patients as 
compared to healthy volunteers (Figure 10A). Specifically, the touch detection 
thresholds in the palm and the forearm were 0.26±0.03g and 0.32±0.04g in the 
volunteers, whereas the respective values for MM patients at these sites were 
0.52±0.07g (P<0.01) and 0.56±0.10g (P<0.05). Importantly, patients exhibited 
significant impairment in Bumps detection (Figure 10B). The mean Bumps detection 
threshold for MM patients was 6.30±0.86 µm but only 3.37±0.38 µm for the volunteers 
(P<0.01). Thus, the Bumps test was more sensitive than von Frey monofilament in 
detecting impaired touch sensation at the fingertip. 
Patients also showed a pronounced impairment in the sensorimotor slotted 
pegboard task (Figure 10C). The completion times for the dominant hand were 
69.36±2.56 seconds for volunteers and 90.63±6.60 seconds for patients; (P<0.01). 
The respective values for the non-dominant hand were 74.30±3.08 seconds and 
86.33±3.20 seconds; (P<0.01). Combined, these findings indicate that MM patients 
with no outward signs or symptoms of neuropathy have impaired Aβ-fiber function and 
dexterity prior to chemotherapy. 
2.3.3 Sharpness Detection Thresholds 
The results of the sharpness detection task are shown in Figure 10D. 
Sharpness detection is a measure of Aδ-fiber function. No significant deficits in 
sharpness detection were observed between the patient and the volunteer groups, 
suggesting that MM does not alter this subset of Aδ-fibers.
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Figure 10 MM Patients Show Differences in Touch Detection and Peg Board 
Performance, But Not Sharpness Detection 
To assess mechanosensation, touch and bumps detection tests were employed 
(A&B). Subjects completed the grooved pegboard as an assessment of sensorimotor 
performance (C). Weighted-blunted needles assessed the ability to detect sharp (D). 
The bar graphs show the mean values (and standard errors) of sensory tests for 
multiple myeloma patients (black bars) and healthy volunteers (gray bars). (A) Touch 
detection (g) determined with von Frey monofilaments measured Aβ-fiber function. (B) 
Dominant and non-dominant hands in completing the slotted pegboard task (s) 
measured sensorimotor function. (C) Bumps detection (µm) was performed using the 
index finger of the dominant hand and measured fine tactile discrimination. (D) 
Sharpness detection threshold (g) measured Aδ-fiber function.   
*= P<0.05, **= P <0.01 
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2.3.4 Skin Temperature and Thermal Detection Thresholds 
Baseline skin temperature was significantly higher at the thenar eminence, but 
not at the other test sites (patients 34.56±0.24 oC vs. 33.66±0.35 oC) (P<0.05) (Figure 
11A). Figure 11 also shows differences between the groups in detection thresholds for 
heat and cold. The MM patient group showed significantly higher (P<0.05) thresholds 
for warmth detection across all three test sites (patients—fingertip: 39.45±0.38 oC 
(P<0.01), thenar eminence:37.83±0.29 oC (P<0.01), volar forearm: 37.78±0.34 oC 
(P<0.05) vs. volunteers—fingertip: 37.90±0.45 oC, thenar eminence: 36.72±0.26 oC, 
volar forearm: 36.54±0.40 oC) (Figure 11B). Heat pain threshold was similar between 
groups at all sites. Heat threshold at the fingertip occurred at the expected range of 45 
to 47oC. Heat thresholds were slightly lower at the thenar eminence and volar forearm 
of both MM patients and healthy volunteers due to inherent differences in the 
sensitivity at the testing site (Figure 11B). The threshold to detect innocuous cool 
sensation was comparable between the patients and volunteers (Figure 11C). 
However, cold pain thresholds were significantly elevated at the thenar eminence and 
volar forearm of MM patients. Mean cold pain thresholds for patients vs. volunteers 
were 14.67±1.55 oC vs. 7.33±1.10 oC at the thenar eminence (P<0.001), and 
13.31±1.62oC vs. 7.46±1.04oC at the volar forearm (P<0.01) (Figure 11C). 
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Figure 11 MM Patients Show 
Differences in Skin Temperature 
and Thermal Detection Thresholds 
The bar graphs show the mean (and 
standard error) (A) baseline skin 
temperature and (B&C) thermal 
detection thresholds (oC) for MM 
patient (black bars) and volunteer 
(gray bars) groups. (B) Warm 
detection (left hand bar group) and 
heat pain threshold (right hand bar 
group). (C) Cool detection (left hand 
bar group) and cold pain threshold 
(right hand bar group).  
*= P<0.05, **=P<0.01 , *** = P<0.001 
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2.3.5 General Neuropathy Score                                                                                                                                      
 An overall neuropathy score was generated for each patient and volunteer by 
summing the number of observations for each subject where any of the measures 
listed above were greater than 2 standard deviations from the mean of the volunteer 
dataset. In total, 22 of 27 (81.5%) patients vs. 10 of 30 (33.3%) of healthy volunteers 
had at least one out-of-range measure (Figure 12). Patients had a mean of 2.48 ± 0.34 
observations of out of range measures. In contrast, volunteers had a mean 0.60 ± 0.19 
out-of-range observations (P < 0.0001) (Figure 12).  
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Figure 12 Greater Numbers of MM Patients Displayed Out-of-Range Measures 
Compared to Volunteers 
The scatter and line plot shows the number of out-of-range measures (measures more 
than 2SD outside the mean) present in individual subjects (cumulative observations). 
(open symbols: healthy volunteers; solid symbols: patients). The inset bar graph 
shows the mean out-of-range QST observations for volunteers (gray bar) and MM 
patients (black bar).  
****= P < 0.0001 
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2.3.6 Quantification of Meissner’s Corpuscles  
A subset of thirteen MM patients and ten healthy volunteers underwent non-invasive 
confocal imaging of the fingertip of the fifth digit (Figure 13A). Two MM patients 
underwent one repeat scan three months after the first scan, for a total of 15 patient 
images that were quantified. To correlate Bumps score with MC density, Bumps 
detection was performed in this patient subset.  Patients had a significantly higher 
mean Bumps score than healthy controls (5.73 ± 0.78 µm and 3.50 ± 0.53 µm 
respectively, P<0.05). Confocal images showed that patients had a decreased mean 
density of MCs as compared to controls (2.63 ± 0.28 MCs /mm2 vs. 4.88 ± 0.62 
MCs/mm2, P<0.01) (Figure 13B).  The Spearman’s Rank-Order correlation was used 
to assess the linear relationship between MC density and Bumps detection threshold.  
As Bumps detection threshold increased, MC density decreased (ρ= -0.69, P<0.001) 
(Figure 13C). 
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Figure 13 Inverse Correlation Between Meissner’s Corpuscle Density and Touch 
Detection 
(A) Representative healthy volunteer and patient images of 1.0 X 1.0 mm in vivo laser 
reflectance confocal micrograph. In the volunteer image, numerous Meissner’s 
corpuscles (MCs) can be seen as white orb shaped structures sitting in the base of the 
dermal papillae (dark circles). Several MCs are indicated by red arrows. Unfilled 
arrows demarcate several of many dermal papillae missing MCs. One MC is visible in 
the patient image. Light color bands are the elevated fingertip ridges. (B) Mean (and 
standard error) Bumps detection score and MC density for a subset of MM patients 
(black bar) and healthy volunteers (gray bar).  (C) The inverse correlation between 
Bumps detection threshold and MC density in patients and volunteers is illustrated in 
the scatter plot. As Bumps detection threshold increases, MC density decreases 
(overall, ρ=0.69, P <0.001).                       
 *= P <0.05, **=P<0.01 
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2.4. Discussion 
The results shown here indicate that subclinical sensory dysfunction consistent 
with early onset neuropathy is highly prevalent in patients with MM prior to 
chemotherapy treatment. Impairments were observed in low-threshold 
mechanosensation, sensorimotor tasks and in thermal detection, consistent with 
dysfunction in Aβ-, Aδ- and C-primary afferent fibers 118-121. MC density on confocal 
scans was similar to MC density quantified in skin biopsies, which suggests that in vivo 
confocal microscopy is a non-invasive, quantitative method to assess MC density 108. 
Patients showed decreased densities of MCs by confocal imaging that were negatively 
correlated with their ability to detect small bumps in the Bumps detection test. These 
data suggests that a decrease in tactile sensitivity is well correlated with MC density as 
visualized by in vivo confocal imaging and is consistent with studies comparing Bumps 
threshold to MC density quantified in skin biopsy 118. Taken together, this suggests 
that nervous system complications are more prevalent in chemotherapy-naïve MM 
patients than previously appreciated.  
Neurological complications in MM are multifaceted. The most common 
neurologic involvement is radicular pain due to spinal cord or nerve root compression 
following lytic bone lesions 121. Consistent with the findings reported here, 
electrophysiological assessments prior to therapy reveal that roughly one third of 
newly diagnosed MM patients have evidence of peripheral nerve involvement 121,122. 
The increased incidence of patients identified with subclinical neuropathy here is 
simply due to the higher sensitivity for quantitative sensory tests to reveal nerve fiber 
dysfunction than electrophysiological methods. The important implication in this work 
is that pre-treatment sensory deficits likely predispose patients to develop drug-
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induced neuropathy because CIPN occurs more frequently and manifests more 
severely in patients with existing neuropathy 106,107,123. 
Neuropathy prior to treatment in MM patients implicates mechanisms based on 
individual and disease-related factors. In part, the patient cohort affected by MM is 
largely an elderly patient population diagnosed at a median age of 66 124.  Advanced 
age is associated with a decline in innervation density (e.g. density of MCs) 125,126. This 
factor was accounted for with an age-match of the non-patient volunteers, indicating 
that a disease-related process is linked with a decrease in MCs in MM patients.  
Despite having a similar age, healthy volunteers had significantly more distal fingertip 
innervation than patient counterparts evidenced by higher MC density. MC density 
visualized on confocal scans was correlated with fine tactile discrimination. Of note, 
healthy volunteers with varying numbers of MCs were able to discern the smallest 
bump during the Bumps test. Thus, individuals with the highest density of MCs may 
have been able to detect bumps smaller than 2.5 µm (the smallest bump used in the 
QST) creating a floor effect in the data and a dampened correlation between MCs and 
tactile discrimination. Despite the presence of a floor effect, individuals who performed 
worse on the tactile discrimination test had lower densities of MCs and more sensory 
abnormalities consistent with sensory neuropathy. These data suggests that in vivo 
confocal imaging may be a novel and sensitive method for early detection of sensory 
deficits consistent with neuropathy. Although this technology is a potentially useful tool 
to quantify peripheral innervation, several limitations of this technology warrant 
mention.  MC innervation is composed of at least two types of C-fibers and both un-
branched and branched Aβ-fibers. It is not clear how long the structure of MCs can 
persist in the absence of innervation by myelinated and unmyelinated sensory fibers, 
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or whether MC structure depends on both or one type of innervation.  While the 
density of MCs is easily quantifiable with in vivo confocal microscopy, innervation of 
the structures cannot be assessed in these images. 
Contributions of the disease process to the generation of neuropathy are well 
documented as overt clinical signs secondary to the plasma cell dyscrasia (particularly 
in POEMS syndrome), or the result of compression of the nerve roots, 
cryoglobulinemia or light chain deposits from amyloidosis 102,127. Amyloidosis refers to 
precipitation of normally soluble protein due to abnormal folding. The most common 
type of amyloidosis is light-chain amyloidosis (AL) and is associated with multiple 
myeloma. In AL, light chains become unstable and self-aggregate forming amyloid 
fibrils in tissues. This can lead to painful, bilateral sensory neuropathy with progressive 
motor involvement 128. POEMS is an acronym that stands for polyneuropathy, 
organomegaly, endocrinopathy, M-protein, and skin abnormalities and refers to a rare 
monoclonal plasmaproliferative disorder associated with osteosclerotic myeloma 129. 
Similar to MM, POEMS patients have monoclonal light chains or immunoglobulins in 
their serum, urine, or bone marrow, and typically suffer from a symmetrical neuropathy 
due to demyelination and axonal loss of primary afferents 130. The development of 
neuropathy in POEMS patients may be due to the secretion of cytokines (e.g. vascular 
endothelial growth factor (VEGF), IL-6, and TNF-α) from abnormal plasma cells and 
plasmacytomas 131. A similar mechanism may be driving the neuropathy in multiple 
myeloma patients. In support of this perspective, MM typically show elevated plasma 
cytokines including elevations in TNF-α and IL-6 132,133.  
Systemic or perineural administration of TNF-α or IL-6, induces mechanical 
allodynia and thermal hyperalgesia 134-137 and an increase in the expression of these 
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pro-inflammatory cytokines following nerve injury is observed in and around peripheral 
nerves and in the DRG 138-140. Peripheral blockade of pro-inflammatory cytokines 
prevents the development of both inflammatory and neuropathic pain. Several 
mechanisms by which pro-inflammatory cytokines influence the function of primary 
afferent neurons have been described 137,141-145. TNF-α has a rapid, sensitizing effect 
on primary afferent neurons resulting in heat-induced CGRP release from nociceptor 
terminals in skin and a lowered activation threshold in Aβ- and C-fibers 146-148; 
mediated at least in part by sensitization of the TRPV1 and TTX-resistant sodium 
channels 149. IL-6 has similarly sensitizing effects on primary afferent fibers through 
both its own receptor mediated signaling as well as by potentially inducing TNF-α 150 
Kelly et al. suggested that neuropathy associated with disease in myeloma is a 
heterogeneous entity resembling carcinomatous neuropathy and that treatment of 
myeloma does not affect the course of neuropathy 151. Others have noted that a 
number of common disorders of the peripheral nervous system, termed 
paraproteinemic neuropathies, are closely connected with the presence of excessive 
amounts of an abnormal immunoglobulin in the blood 152. In at least some patients, 
these antibodies are directed at components of myelin or the axolemma, resulting in 
complement mediated damage to Schwann cells and axons 152. Yet, baseline testing 
of colorectal cancer patients with no clinical evidence or reported symptoms of 
neuropathy prior to chemotherapy revealed subclinical peripheral neuropathy is a 
surprisingly common occurrence (an incidence of 46 of 52 subjects) in this type of 
cancer as well 153.  This suggests that cancers in general engage biological responses 
that impair nerve function. Given the strong connection between pre-existing 
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neuropathy and its exacerbation by disease treatment, these findings underscore the 
need for careful screening and individualized treatment plans for patients at risk.  
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3. Preliminary analysis of a phase I study of minocycline vs. placebo to prevent 
treatment-induced neuropathy in multiple myeloma 
  
3.1. Introduction         
     To address Hypothesis 2 of this thesis, the goal of this section was to investigate 
whether the antibiotic, minocycline, administered orally during the course of 
bortezomib treatment, would prevent sensory neuropathy induced by bortezomib and 
decrease patient-reported symptoms of neuropathy. Below is an overview of 
minocycline and its potential utility in preventing or treating neuropathic pain and 
neurodegenerative disorders.  
     Neuropathic pain is a catch-all description for a spectrum of abnormal sensory 
symptoms that arise due to peripheral or central nervous system damage and can 
affect diverse areas of the body depending on the underlying root cause 45. As 
discussed in Chapter 1, CIPN is a side-effect of chemotherapy that interferes with 
quality of life for patients and compels providers to scale back chemotherapeutic dose. 
Neuropathic pain conditions, including CIPN, are often chronic and debilitating medical 
conditions that are either incompletely managed by, or refractory to opioids and 
medications purposed to treat neuropathic pain (e.g. gabapentin and pregabalin) 154. 
Chemotherapy is a scheduled, non-emergency treatment. The most efficient 
treatments for CIPN will be preventative measures, rather than reactive medications to 
treat already established symptoms of neuropathy. The search for more efficacious 
treatments with improved side effect profiles is warranted.  
        Minocycline is an FDA-approved tetracycline-derived antibiotic predominately 
used in the treatment of acne vulgaris. Minocycline is part of a larger class of 
tetracyclines, considered broad-spectrum antibiotics effective in eradicating both gram-
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positive and gram-negative bacteria. Tetracyclines interfere with bacterial protein 
production by binding to the bacterial 30S ribosome subunit and inhibiting translation 
of mRNA into polypeptide chains 155. Minocycline is a second-generation tetracycline, 
chemically engineered to have increased absorption and bioavailability due its 
lipophilic properties and effectively crosses the blood-brain barrier 156. In addition to 
well-documented efficacy as an antibiotic, there is a large body of literature that 
indicates that minocycline can be used to treat an array of diseases and conditions 
through its diverse properties. In the past twenty years, minocycline has been shown 
to have anti-inflammatory, immunomodulatory, and neuroprotective effects in both 
clinical and pre-clinical studies that suggest a potential therapeutic effect in the 
treatment of rheumatoid arthritis, ischemia, aortic aneurysms, cancer metastasis, 
traumatic brain injury, spinal cord injury, Parkinson’s disease, Huntington’s disease, 
multiple sclerosis and neuropathic pain, among others.155. The neuroprotective 
properties of minocycline have been attributed to cellular actions, including the ability 
to inhibit microglial activation, microglia-induced release of pro-inflammatory cytokines, 
apoptosis, as well as its anti-oxidant properties 157. In rodent models of CIPN, pre-
treatment with minocycline attenuates hypersensitivity, prevents the loss of 
intraepidemal nerve fibers, the activation of astrocytes and the downregulation of 
astroglial glutamate transporters, GLAST and GLT-1.   Furthermore, the use of 
minocycline as a neuroprotective agent has yielded favorable results in several clinical 
studies with minimal adverse events 158,159. Spinal cord injury patients treated with 
minocycline showed improvement in motor performance in a phase II placebo-
controlled randomized trial, though statistical significance was not achieved 160. Pre-
clinical literature indicates that minocycline can prevent the onset of neuropathic pain, 
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but cannot reverse pre-established neuropathic pain, making its application ideal as a 
preventative treatment 161. These findings, combined with its success in preventing the 
development of CIPN in rodents 162,163 suggests that minocycline may be an attractive 
candidate for use in the clinical treatment of CIPN.  
        As previously discussed in section 1.4, treatment of multiple myeloma with the 
frontline-chemotherapeutic agent, bortezomib, causes dose-dependent sensory 
neuropathy as a side-effect 86. Bortezomib-induced neuropathy (BIPN) causes 
discomfort and more importantly, frequent dose reductions, which limit its anti-cancer 
efficacy. Bortezomib-treated patients show impairments in Aβ-, Aδ-, and C-primary 
afferent subtypes by QST 109. These clinical findings complement the changes seen in 
the primary afferent neurons, DRG and spinal cord of bortezomib-treated rodents 90. 
Changes in sensory ganglia neurons due to bortezomib include nucleolar hypertrophy, 
upregulation of rRNA synthesis, damage of mitochondria and recruitment of satellite 
glial cells 90,164. The literature presents mixed findings about the duration and 
reversibility of clinical BIPN. Some studies report median times to improvement of 
neuropathy grade to be 3 to 4 months for grade 1 or 2 neuropathy and 8 months for 
grade 3 or 4 neuropathy 165. Other quantitative studies report BIPN-induced sensory 
deficits that are detectable as far as one year following treatment 89. To investigate the 
hypothesis that oral minocycline administered with the chemotherapeutic agent, 
bortezomib, would prevent sensory neuropathy induced by bortezomib and decrease 
patient-reported outcomes of neuropathy, quantitative sensory thresholds and patient-
reported outcomes were compared to patients randomized to placebo in a double-
blind clinical trial.    
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3.2. Subjects and Methods 
3.2.1 Study Site 
        This study was conducted at the University of Texas MD Anderson Cancer 
Center, Houston, TX from March 2011 to October 2013. All enrolled subjects provided 
written and oral informed consent and were explained the risks and benefits of 
participating in this Phase I protocol as reviewed and approved by the Institutional 
Review Board of UT MD Anderson Cancer Center. All subjects signed a written 
informed consent before they were enrolled in the study and data was collected. 
3.2.2 Study Design 
     This was a double blind, Phase I, randomized placebo-controlled clinical study to 
assess the efficacy of minocycline in preventing bortezomib-induced neuropathy.  MM 
patients underwent QST (including quantitative and qualitative measures) after 
myeloma diagnosis, but prior to beginning chemotherapy as previously described in 
Chapter 2. Subjects were then randomized to receive either minocycline 200 mg, or 
placebo orally for the first dose, and then 100 mg twice a day for the next ten weeks. 
Patients were counseled on accountability and willingness to comply with taking the 
study drug as prescribed. The study drug was mailed to study participants with 
instructions to begin the first dose on the first day of the first cycle of chemotherapy 
treatment. A follow-up quantitative sensory testing was performed on patients during 
the course of chemotherapy and minocycline/placebo treatment. The primary endpoint 
of this study was fingertip touch detection threshold. 
3.2.3 Randomization and Blinding 
        Study participants were registered in the institutional database Clinical Oncology 
Research system (CORe) and randomized to receive placebo or minocycline. This 
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information was provided to the institutional pharmacy for disbursement to study 
participants. Pharmacy personnel did not interact with personnel collecting the data or 
with healthcare providers and were separated by space and department. The 
pharmacy maintained records of the randomization list. After seventy-two patients 
were enrolled, the randomization list was provided to the institutional statistical 
department for analysis.  
3.2.4 Inclusion and Exclusion Criteria 
        Study inclusion criteria were men and women greater than 18 years of age newly 
diagnosed with symptomatic MM, having previously received no chemotherapeutic 
treatment, but scheduled to receive bortezomib as part of induction therapy for their 
disease. Additionally, included patients exhibited no symptoms of neuropathy at 
baseline as per physician’s clinical assessment, and pre-menopausal female patients 
were willing to use adequate birth control for the duration of the study. Patients were 
also required to read and speak English. Patients with a documented allergy to 
tetracycline, history of poorly controlled or advanced diabetes mellitus (lab value HA1c 
≥ 8%), signs and symptoms of progressive or uncontrolled renal, hepatic, 
gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease 
documented, peripheral neuropathy of ≥ grade 2 by CTCAE Version 4.0 as per 
treating physician, history of malignancy other than MM or a history in the last 5 years, 
and significant drug or alcohol use as per social history clinic notes were not 
approached for consent. 
3.2.5 Protocol Deviations 
        Deviations from the protocol include individuals who consented to the study, but 
had already begun induction therapy and therefore did not provide a baseline test. 
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Furthermore, these same individuals were administered the first dose of minocycline 
or placebo after induction of chemotherapy. 
3.2.6 Clinical Outcome Measures and Methods 
        Sensory function was assessed by QST on three skin sites: fingertip, thenar 
eminence and volar forearm. The primary study endpoint was the touch threshold of 
the fingertip. All QST data was collected by research coordinators blind to study group 
and experimental design. Sensory testing assessing skin temperature, touch detection 
(von Frey and Bumps test), temperature threshold (detection of warm, cool, noxious 
heat, and noxious cold), and sharp detection were performed on three skin sites: 
fingertip, palm and forearm and a sensorimotor pegboard task was administered as 
described in Chapter 2. Patient-reported outcomes were also assessed. 
3.2.7 Safety and Tolerability 
     Previous studies evaluating the safety of 200 mg/day oral minocycline reported no 
major concerns and an adverse event profile similar to the placebo group 166. Adverse 
events were monitored continuously throughout the study and several patients 
discontinued the study drug. 
3.2.8 Statistics 
        All analyses were performed using GraphPad Software, Inc. (La Jolla, CA). 
Fisher’s exact test was performed to compare frequency distribution for categorical 
variables. Continuous variables (QST measures) were compared between placebo 
and minocycline groups with the Kruskall Wallis test (the non-parametric equivalent of 
the one-way ANOVA). To compare patients’ initial with follow-up QST, the paired on-
parametric Wilcoxon-rank sum test was used. No adjustment was made for performing 
multiple tests, as this was an exploratory study. Due to the complexity of the data set 
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the UT MD Anderson Department of Biostatistics was consulted to perform additional 
analyses. These included a backward stepwise regression approach to select 
variables to include in a multivariable analysis. The results of the multivariable analysis 
can be found in Chapter 5, Appendix B.  
3.2.9 Ethics 
        This study was approved by the Internal Review Board of UT MD Anderson 
Cancer Center and conducted in accordance with the principles of the Declaration of 
Helsinki and the Guidelines of Good Clinical Practice.  
3.3. Results 
3.3.1 Patient Population Analyzed 
        A total of 72 patients met the inclusion criteria of the study, signed the necessary 
informed consent documents and completed at least one QST. Follow-up tests (tests 
conducted after baseline) were administered after chemotherapy treatment was 
initiated, when patients returned to the hospital for their necessary clinic appointments. 
Although this testing schedule was the most convenient option for patient schedules, 
patients had different cumulative doses of bortezomib at the time of testing. 
Bortezomib was typically administered to patients on days 1, 4, 7, and 11 of a 21-day 
cycle at a dose of 1.3 mg/m2, but some patients received a modified version of the 
standard dosing due to advanced age, the development of neuropathy, or the use of 
adjunctive agents. Bortezomib-induced neuropathy literature suggests that the 
development of neuropathy in patients is most likely dose-dependent in nature, with 
symptoms worsening as cumulative dose increases 86. Therefore, the cumulative dose 
of bortezomib (in total milligrams) at each test for each patient was calculated to 
standardize the analysis. Over the course of the study, patients were tested at 
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cumulative bortezomib doses ranging from 0 mg to 53.8 mg. Due to the variability in 
cumulative dose and number of days between the start of bortezomib and the study 
drug (minocycline or placebo), the approach taken in this analysis was to first analyze 
a subset of the patients that met all of the initial inclusion criteria for the study 
(including a baseline test) and subsequently, to expand the analysis to include a 
greater number of patients. Preliminary analysis of primary endpoints did not reach 
statistical significance and the study was then closed to future patient entry. 
        Patient inclusion is depicted in Figure 14. Of the 72 patients initially enrolled in 
the study, three patients were removed upon patient request. Two patients were 
removed prior to completion due to adverse events. Of these, the first patient was 
disenrolled after 24 days of taking the study drug due to high liver function enzymes; at 
the conclusion of the study, the patient was found to be in the placebo group, 
indicating that high liver function enzymes was unrelated to the study drug. The other 
patient was disenrolled after two weeks of taking the study drug due to the 
development of a rash. This patient was also in the placebo group. Two additional 
placebo patients discontinued the medication for four days or less during the study due 
to a presumed allergic reaction. Only one of these patients was included in the final 
analysis.  
        Nineteen patients received a baseline test prior to the start of bortezomib and a 
follow-up test during bortezomib treatment. These patients were used for the initial 
analysis. A second analysis was performed by grouping 32 patients with a low dose of 
chemotherapy with the 19 patients who had received a baseline test for a total of 51 
patients. The patients excluded from this analysis lacked an initial test at <13 mg 
bortezomib or a follow-up test at >13 mg bortezomib.  
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Figure 14 Study Design 
Flow-chart of patients excluded or included in the analysis.  
 
3.3.2 Analysis #1 
3.3.2.1 Patient Demographics          
        The first group of patients analyzed (N=19; Placebo: n= 9, Minocycline: n=10) all 
received a “true” baseline test (prior to the start of chemotherapy), began taking the 
study drug (placebo or minocycline) no later than a week after induction 
chemotherapy, and received a follow-up test at cumulative doses in the range of 14.0 
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mg to 52.8 mg. A cumulative dose of 14.0 mg roughly corresponds to greater than 1.5 
cycles of bortezomib. Due to the already limited sample size, 14.0 was arbitrarily 
chosen as the smallest cumulative dose bortezomib at follow-up test to maximize 
inclusion of patients. Differences in demographic variables were assessed with the 
non-parametric Mann Whitney test for continuous variables or Fisher’s exact test for 
discrete variables. Age, sex, and cumulative dose at follow-up test were not 
significantly different between the two groups. The minocycline group had significantly 
more patients who had undergone radiation treatment prior to their baseline test. 
Radiation treatment has the potential of damaging peripheral nerves, although 
symptoms of damage often surface years after treatment 167. Because these patients 
had received radiation therapy just prior to the baseline test and because baseline 
QST did not significantly differ between the two groups, it was considered reasonable 
to proceed with the analysis.   
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Table 4 Patient Demographics: Analysis #1 
Median patient age and cumulative dose were similar between placebo (n=9) and 
minocycline (n=10) groups. The numbers of females and males did not differ between 
minocycline and placebo groups, however, significantly more patients in the 
minocycline group had received prior radiation treatment.  
*=P<0.05 
 
 
        Each of the groups (placebo and minocycline) received a baseline test and a 
follow-up test during concurrent study drug administration and bortezomib treatment 
(≥13 mg). The analysis consisted of four groups:  (placebo at baseline (placebo-
baseline), placebo-post-chemotherapy (placebo-post-chemo), minocycline at baseline 
(minocycline-baseline), and minocycline-post-chemotherapy (minocycline-post 
chemo). Intragroup comparisons (between placebo-baseline and placebo-post-chemo; 
minocycline-baseline and minocycline-post-chemo) were performed with the paired 
non-parametric Wilcoxon-rank sum test. Intergroup comparisons (between placebo-
post-chemo and minocycline-post-chemo) were performed with the non-parametric 
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Kruskal-Wallis test. The minocycline-post-chemo and placebo-post-chemo groups 
were denoted with the word “max” in all graphs in this analysis. 
3.3.2.2 Touch Detection 
       To assess Aβ-fiber function, mechanical sensitivity of patients was tested. Touch 
detection measured with von Frey monofilaments at the volar forearm was significantly 
higher in the placebo group post-chemo treatment (0.33±0.10g at baseline versus 
0.73±0.21g post-chemo, P=0.03) (Figure 15A), indicating a reduction in tactile 
perception at this site. No significant differences were observed at the fingertip or 
thenar eminence, or between the other groups. The Bumps detection test measures 
fine tactile discrimination of the fingertip. No significant differences were observed in 
Bumps detection thresholds of placebo and minocycline groups at either baseline or 
post-chemo (Figure 15B).  A comparison of baseline versus post-chemo for both von 
Frey touch detection and Bumps detection tests suggests that bortezomib does not 
alter fine tactile discrimination in placebo-treated MM patients.  
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Figure 15 Touch and Bumps Detection Thresholds Showed Few Differences 
Between Minocycline and Placebo Groups 
(A) Touch threshold measured with von Frey monofilaments at the fingertip, thenar 
eminence and volar forearm for the placebo group (black bars) and the minocycline 
group (gray bars) at baseline (0 mg) and post-chemotherapy treatment (Max). Touch 
threshold in the placebo group significantly increased at the volar forearm after 
chemotherapy, but did not differ between any other groups at any other sites. (B) Fine 
tactile discrimination of the fingertip assessed with the Bumps detection test. No 
significant differences were observed.  
*= P<0.05 
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3.3.2.3 Peg Board Completion, Sharpness Detection and Skin 
Temperature 
        The peg board completion task assessed dexterity by measuring the latency for 
subjects to fit odd-shaped pegs into corresponding holes in a board. The minocycline 
group exhibited significantly faster completion of the pegboard with the dominant hand 
after bortezomib treatment (75.5±4.9 s) compared with their baseline test (84.6±4.5 s) 
(P=0.01) (Figure 16A). However, completion times did not differ significantly between 
the minocycline group post-chemo and the placebo group post-chemo. Completion 
times for the non-dominant hand did not differ within or between groups.     
        No significant differences were observed in the sharpness detection test or in skin 
temperature (Figure 16B&C). 
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Figure 16 Minocycline Group Showed Faster Dominant Hand Peg Board 
Completion, but No Differences in Sharpness Detection and Skin Temperature 
(A) The time to fit pegs in a pegboard for placebo (black bars) and minocycline (gray 
bars) groups. The minocycline group had significantly faster completion times after 
bortezomib (P=0.01), but there was no significant difference between the minocycline 
and placebo groups post-chemotherapy treatment (Max). (B) Sharpness detection was 
assessed (C) Skin temperature was measured. No significant differences were 
observed in sharpness detection or skin temperature. 
*=P<0.05 
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3.3.2.4 Temperature Detection        
        For temperature detection, patients reported the first detection of a change in the 
temperature of a probe (“cool” or “warm”) and then, when the temperature became 
painfully cold or hot as a measure of both C- and Aδ-fiber function. The temperature at 
which subjects first reported feeling “cool” significantly increased for both placebo 
(24.54±2.40 °C) and minocycline (24.55±0.83 °C) groups post-chemotherapy as 
compared to respective baseline tests (22.04±0.78 °C and 22.99±0.84 °C, P= 0.03 and 
P=0.04) at the fingertip (Figure 17A). However, there was no difference in the cool 
fingertip threshold of placebo-post-chemo and minocycline-post-chemo. This suggests 
that an increased ability to detect cool is not impacted by treatment with minocycline. 
The inverse was seen at the thenar eminence and volar forearm. At both the thenar 
eminence and volar forearm, ability to detect cool decreased in the placebo-post-
chemo group. The threshold at the thenar eminence in the placebo-post-chemo group 
was 15.18±1.60 °C, which was significantly lower than 26.08±0.81°C in the placebo 
group at baseline (P=0.004) and 24.49±1.25 °C in the minocycline-post-chemo group 
(P<0.01).  The threshold at the volar forearm for the placebo-post-chemo group was 
14.24±2.22 °C, which was significantly lower than the placebo group at baseline 
(25.12±0.77 °C, P=0.004) and the minocycline-post-chemo (23.10±1.50 °C, P<0.01). 
These data suggest the placebo group was less able to detect cool temperatures after 
chemotherapy treatment at the volar forearm and that minocycline may preserve cool 
detection at these sites. 
     Cold pain threshold increased significantly at the fingertip and thenar eminence in 
the minocycline-post-chemo group as compared with the minocycline-baseline group, 
9.77±2.46 vs. 6.54±1.76 (P=0.002), respectively, at the fingertip and 14.98±2.57 vs. 
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13±2.57 (P=0.048), respectively, at the thenar eminence) (Figure 17B). No other 
significant differences were observed in cold pain thresholds. The patterns in cool 
detection would have been expected if the minocycline had a neuroprotective effect. 
However, the minocycline-post chemo group showed increases in cold pain that do not 
support a neuroprotective role of minocycline in nociceptive cold fibers. 
       Bortezomib-induced peripheral neuropathy is thought to affect C-fibers controlling 
warm and heat pain 89,109 therefore, these modalities were assessed with a Peltier 
thermode (Chapter 2, Figure 7). No significant differences were observed within or 
between any groups in warmth detection and heat pain thresholds (Figure 18A&B). 
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Figure 17 Minocycline and Placebo Groups Exhibit Differences in Cool 
Detection, and Minocycline Does not Attenuate Increases in Cold Pain 
Thresholds 
(A) Cool detection threshold measured at the fingertip, thenar eminence and volar 
forearm for the placebo group (black bars) and the minocycline group (gray bars). Cool 
detection threshold in the placebo and minocycline groups significantly increased at 
the fingertip after chemotherapy, but did not differ between any other groups. At the 
palm and forearm, the cool threshold was significantly lower in the placebo group after 
chemotherapy indicating less ability to discriminate cold. (B) Cold pain threshold 
increased at the fingertip and palm in the minocycline group after chemotherapy. No 
differences in cold pain at the volar forearm were noted.  
*= P<0.05, **=P<0.01 
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Figure 18 Warmth and Heat Pain Thresholds Were Not Different Between 
Minocycline and Placebo Groups 
(A) Warmth detection threshold measured at the fingertip, thenar eminence and volar 
forearm for the placebo group (black bars) and the minocycline group (gray bars). (B) 
Heat pain thresholds were measured at the same sites. No significant differences were 
found in warmth detection or heat pain thresholds. 
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3.3.2.5 Rationale for Performing Analysis #2 
The pilot study was not suggestive of any conclusive trend regarding the impact of 
bortezomib on QST with or without minocycline. Due to the small sample size, it was 
decided to utilize less stringent inclusion criteria to expand the number of patients 
analyzed. Thirty-two of 72 patients did not have a baseline test prior to beginning 
chemotherapy treatment, but did have a test performed at a low dose of bortezomib 
(less than 13 mg of bortezomib) and a follow-up test performed during course of 
treatment with bortezomib. These patients were added to the previously analyzed 
group for a total of 24 patients randomized to receive placebo and 27 to receive 
minocycline. First, it was important to determine whether it was appropriate to combine 
the QSTs of patients at a true baseline with QSTs of patients at a low initial dose of 
bortezomib. To assess this, QSTs of patients randomized to placebo with a true 
baseline were compared to those at a low dose of chemotherapy for all tests (e.g.: 
Bumps, touch, and temperature detection, etc.) at all sites (e.g.: fingertip, palm, 
forearm) using the non-parametric Mann-Whitney test. Although none of the 
comparisons were statistically significant, the Bumps test approached statistical 
significance with a mean Bumps detection threshold of 4.5±0.71 µm in the placebo-
baseline group versus 7.28±0.94 µm in the placebo group with a low initial cumulative 
dose bortezomib (P=0.07, Figure 19A). The increase in Bumps detection threshold in 
the placebo group with a low dose of bortezomib could not solely be explained by the 
infusion of chemotherapy because the age of the two groups also approached a 
statistically significant difference (placebo: 56±2.39 years, low-dose: 62.13±1.96 years, 
P=0.07, Figure 19B). Fine tactile discrimination decreases with age 126,168; therefore, 
these differences could have been age-related rather than due to bortezomib infusion . 
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In addition, no difference in Bumps detection was observed in the previous analysis in 
the placebo group before and after chemotherapy (Figure 15B). Therefore, it was 
deemed appropriate to group together the patients with a low dose of chemotherapy 
and the patients with a baseline to compare initial and follow-up QSTs. QST tests were 
compared as described above using the nonparametric Wilcoxon matched-pairs test 
within groups (e.g.: placebo-initial versus placebo-follow-up ) and the non-parametric 
Kruskal-Wallis test between groups (e.g.: placebo-follow-up versus minocycline-follow-
up).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 19 Bumps Detection and Age of Placebo 
Reach Statistical Significance Between Placebo 0mg Versus Low
Bortezomib   
(A) Bumps detection and 
bars) versus placebo low dose 
(P=0.07), but did not reach statistical significance.
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3.3.3 Analysis # 2 
3.3.3.1 Patient Demographics 
        A total of 51 patients were analyzed in the subsequent analysis expanded to 
include patients with an initial test performed at a low initial dose of bortezomib, and a 
follow-up test at a higher cumulative dose bortezomib. The median age of the placebo 
group (n=24) and minocycline (n=27) group was 61.5 and 58 years old, respectively 
(P=0.79). Sex, previous radiation treatment and cumulative dose of bortezomib at 
follow-up test were not different between the two (Table 3.2).  
 
Table 5 Patient Demographics: Analysis #2  
Median patient age and cumulative dose were similar between placebo (n=24) and 
minocycline (n=27) groups. The numbers of females vs. males and the number of 
patients who had received prior radiation were also similar between minocycline and 
placebo groups.  
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3.3.3.2 Touch Detection 
        No significant differences were observed in fingertip and thenar eminence touch 
detection using von Frey filaments (Figure 20A). Touch detection threshold at the volar 
forearm was significantly lower in the minocycline group at follow-up as compared with 
their initial test (0.44±0.05 g vs. 0.52±0.02 g, P=0.01). Lower thresholds indicate better 
touch detection. Interestingly, the touch threshold at this site was not significantly 
different between the two follow-up groups (minocycline and placebo). Similarly, 
Bumps detection threshold was significantly higher in the minocycline-follow-up group 
as compared to their initial test (minocycline-follow-up: 7.14±0.84 vs. minocycline-
initial: 5.80± 0.74, P=0.03) (Figure 20B), indicating worsening fine tactile 
discrimination. Bumps detection for minocycline-follow-up group was not significantly 
different from the placebo-follow-up group. 
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Figure 20 Touch Detection at Volar Forearm Improved and Bumps Detection at 
the Fingertip Worsened in the Minocycline-Follow-Up Group 
(A) Touch threshold was measured with von Frey monofilaments at the fingertip, 
thenar eminence and volar forearm for the placebo group (black bars) and the 
minocycline group (gray bars). Touch threshold in the minocycline group significantly 
decreased at the volar forearm after chemotherapy, but did not differ between any 
other groups at any other sites. (B) Bumps detection threshold. Fine tactile 
discrimination of the fingertip significantly increased in the minocycline follow-up 
group.  
*= P<0.05 
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3.3.3.3 Peg Board Completion, Sharpness Detection and Skin 
Temperature 
        The completion time for peg board was significantly shorter in the minocycline-
follow-up group as compared to their initial test (follow-up: 78.71±3.57 s vs. initial: 
83.45±3.52 s) (Figure 21A). There were no differences in sharpness detection and 
skin temperature between any of the groups (Figure 21B&C).  
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Figure 21 Peg Board Completion, Sharpness Detection, and Skin Temperature 
(A) The latency to fit pegs in a pegboard was compared between placebo (black bars) 
and minocycline (gray bars) groups. The minocycline-follow-up group had significantly 
faster completion times compared to minocycline-baseline (P<0.05), but there was no 
significant difference between minocycline-follow-up and placebo-follow-up groups. (B) 
Sharpness detection was assessed. (C) Skin temperature was measured. No 
significant differences were observed in sharpness detection or skin temperature. 
*=P<0.05 
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3.3.3.4 Temperature Detection 
The temperature for detecting “cool” was not significantly different between the 
placebo and minocycline groups at follow-up test, however, both groups had cool 
detection thresholds that were significantly higher in temperature when compared to 
respective initial tests (placebo-follow-up: 24.02±0.63 °C, placebo-initial: 21.89±0.56 
°C, P=0.007) and (minocycline-follow-up: 24.21±0.46 °C, minocycline-initial: 
22.69±0.50 °C, P=0.003) (Figure 22A). Cool threshold at the volar forearm was 
significantly higher in the placebo-follow-up group compared to the initial test (placebo-
follow-up: 25.81±0.31°C vs. placebo-initial: 24.43±0.56°C, P=0.03) (Figure 22A). There 
were no significant differences in the cool threshold at the thenar eminence.  
        Cold pain thresholds were parallel to cool thresholds. The cold pain fingertip 
thresholds in both minocycline and placebo groups at follow-up were significantly 
higher than respective initial tests (placebo-follow-up: 12.57±1.57 °C vs. placebo-
initial: 7.39±1.27 °C, P=0.005 and minocycline-follow-up: 9.77±1.23 °C vs. 7.18±1.05 
°C minocycline-initial, P=0.003) (Figure 22B). There were no significant differences in 
cold pain at the thenar eminence and volar forearm (Figure 22B).  
       There were no significant differences in warm detection thresholds at any site 
(Figure 23A).  
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Figure 22 Fingertip Cool and Cold Pain Thresholds   
(A) Cool detection threshold measured at the fingertip, thenar eminence and volar 
forearm for the placebo group (black bars) and the minocycline group (gray bars). Cool 
detection threshold in the placebo-follow-up and minocycline-follow-up groups 
significantly increased at the fingertip compared to their respective initial tests. At the 
forearm, the cool threshold was significantly higher in the placebo-follow-up group. No 
differences in cool detection were seen at the palm. (B) Cold pain threshold increased 
at the fingertip in both placebo and minocycline-follow-up group. 
*= P<0.05, **=P<0.01 
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Figure 23 Warm and Heat Pain Thresholds 
(A) Warmth detection threshold measured at the fingertip, thenar eminence and volar 
forearm for the placebo group (black bars) and the minocycline group (gray bars). No 
significant differences were found in warmth threshold. (B) Heat pain thresholds 
measured at the same sites. Heat pain in the placebo-follow-up group occurred at 
significantly lower temperatures than the minocycline-initial group. 
*=P<0.05 
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3.3.3.5 Patient Reported Symptom Descriptors 
 
        Rates in patient-reported tingling and numbness were analyzed. As expected, 
initial rates of tingling and/or numbness were not different between minocycline and 
placebo groups. At follow-up test, 10 of 27 patients reported tingling and 10 of 27 
reported numbness in the minocycline group (Figure 24B&D). In the placebo group 11 
of 24 patients reported numbness and 14 of 24 reported tingling (Figure 24A&C). 
Rates of tingling were lower in the minocycline-follow-up group compared to placebo-
follow-up group, but statistical significance was not achieved (P=0.11). Patient-
reported numbness was not statistically significant between minocycline-follow-up and 
placebo-follow-up groups by the Fischer’s exact test. However, placebo group reports 
of numbness significantly increased at follow-up with 4 patients reporting tingling at the 
initial test compared to 14 at the follow-up test (P=0.007) (Figure 24A). Placebo group 
reports of numbness approached a statistically significant increase after bortezomib 
treatment (at follow-up) (P=0.06) (Figure 24C). No significant differences were 
observed between minocycline-patient reported tingling and numbness at the follow-up 
test (Figure 24B&D). 
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Figure 24 Patient Descriptors 
(A&B) The number of patients in placebo and minocycline groups who reported 
numbness (black bars) or did not report numbness (gray bars) during initial and follow-
up tests, respectively. (C&D) Rates of tingling in both groups. Significantly more 
placebo patients reported numbness after bortezomib as compared to at the initial test. 
No other significant differences were observed.  
**=P<0.01 
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3.4. Discussion  
        The present study describes the sensory function of multiple myeloma patients 
treated with chemotherapy, including, but not limited to bortezomib, and randomized to 
receive minocycline (200 mg/day for ten weeks) or placebo. The first analysis was 
performed on patients, who had received baseline testing before chemotherapy. The 
second analysis included additional patients, who received initial testing immediately 
following induction therapy with a low cumulative dose of bortezomib. All patients 
received a follow-up test during the course of their chemotherapy treatment for 
comparison. The hypothesis that co-administration of minocycline with bortezomib 
would prevent changes in sensory thresholds induced by bortezomib was not 
supported. Although patients randomized to receive oral minocycline with bortezomib 
treatment displayed few differences in sensory thresholds as measured with QST, 
placebo-treated patients did not develop quantifiable sensory deficits after bortezomib 
treatment. The hypothesis that administration of minocycline during chemotherapy 
treatment would improve patient-reported outcomes was moderately supported by a 
reduction in the rates of tingling and numbness in patients randomized to minocycline, 
although statistical significance was not achieved.   
        Surprisingly, the placebo group in this study showed no overall detectable decline 
in sensory function after chemotherapy treatment. The cool detection thresholds of the 
palm and forearm in Analysis #1 were the only tests in which the placebo group 
displayed a significant decline in sensory perception after chemotherapy treatment 
(Figure 17). All other tests either showed no significant differences or improvement of 
sensory perception after chemotherapy (Figures 16 and 18-23). Despite the lack of 
decline in sensory function by QST, patient reports of tingling in the placebo group 
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significantly increased from 16.7% at the initial test to 58.3% at the follow-up test. 
Patient-reported rates of numbness approached, but did not reach a statistically 
significant difference in the placebo group (P=0.06) (Figure 24B). Patients treated with 
placebo throughout the course of bortezomib treatment reported increased tingling and 
numbness at the follow-up test, suggesting that they had developed neuropathy. 
Despite an increase in patient-reported symptoms consistent with neuropathy, no 
differences in sensory thresholds were measured with QST after chemotherapy 
treatment. The seeming incongruence between patient-reported and QST data may be 
because patients reported symptoms that were present in their distal extremities, 
which included hands and feet, but sensory thresholds were only measured in the 
hands. Clinicians note that bortezomib-induced neuropathy presents sooner, more 
frequently, and more severely in the feet as opposed to the hands (unpublished 
observation). Given the short ten-week interval between initial and follow-up testing it 
is possible that sensory thresholds in the hands were not yet affected by the 
bortezomib treatment. It is also a possible that patient-reported symptoms of 
neuropathy precede measurable changes in sensory threshold measured with QST.   
        There are several other possible explanations for the lack of change in sensory 
thresholds in MM patients treated with bortezomib and placebo. First, Analysis #1 was 
conducted in a very small set of patients (n=9 in the placebo group) making it difficult 
to see reliable changes. Analysis #2 was conducted in larger number of patients, but 
the majority of these patients underwent initial testing after a small cumulative dose of 
chemotherapy. Treatment-emergent peripheral neuropathy can occur in 21% and 37% 
patients given a single dose of 1.0 mg/m2 and 1.3 mg/m2, respectively 85. Therefore, 
sensory changes could have already occurred in some patients prior to receiving the 
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initial test, making it difficult to detect significant changes at the follow-up test. In fact, 
when the baseline test of placebo patients with no prior chemotherapy was compared 
to placebo patients with a small cumulative dose of chemotherapy, the Bumps 
detection test showed a reduced fine tactile discrimination that approached 
significance (P=0.07) (Figure 19A). However, this near-significant difference could not 
solely be attributed to chemotherapy treatment because the mean age of the latter 
patient group was higher (P=0.07). There is an age-related decline in tactile perception 
168
, therefore, it remains unclear as to whether this difference in tactile perception was 
due to aging of the somatosensory system or to chemotherapeutic treatment.  
        In addition, literature reports the peak of BIPN symptoms to occur at 
approximately the fifth cycle of chemotherapy. The follow-up test conducted on this 
group of patients occurred less than 10 weeks after starting treatment, meaning that 
most patients were tested prior to the fourth cycle of bortezomib. Previous studies 
report that patients tested during, and at a year post-bortezomib show similar 
magnitudes of QST deficits 89. The stability and lack of worsening in initial versus 
follow-up sensory testing of placebo patients in the present study, together with a lack 
of improvement at one year post-treatment may be indicative of “coasting.” Although 
typically associated with the platin therapies (e.g. cisplatin and oxaliplatin), coasting 
refers to symptoms that develop late, but persist or worsen after the end of therapy.           
        Another possible explanation for the lack of treatment-emergent differences in the 
QSTs of placebo patients is the presence of a disease-related neuropathy. Several 
studies acknowledge the existence of these subclinical deficits most likely related to 
primary cancer 169. Previous psychophysical studies perhaps fail to report subclinical 
sensory deficits in treatment-naïve MM patients due to small sample size 109. Future 
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QST studies should focus on distinguishing treatment-related from cancer-related 
sensory deficits and should investigate whether sub-clinical deficits are associated 
with an increased susceptibility for developing CIPN.  
        In the spinal nerve ligation (SNL) model of neuropathic pain, minocycline 
attenuates mechanical hypersensitivity when administered at post-operative day 1 and 
3, but cannot reverse established hypersensitivity when administered at later time 
points 161. In the SNL rodent model of neuropathic pain, the activation of microglia is 
thought to contribute to the development of mechanical hypersensitivity through the 
release of inflammatory cytokines 149.  The attenuation of neuropathic pain by 
minocycline is hypothesized to be due to its suppressive effects on the activation of 
microglia 170. This proposed mechanism of action, however, does not account for 
minocycline’s efficacy in preventing neuropathic pain caused by chemotherapy, as 
rodents treated with chemotherapy do not show microgliosis 171. In CIPN rodent 
models the ability of minocycline to block hypersensitivity is likely related to prevention 
of astrocyte proliferation and prevention of a chemotherapy-induced downregulation of 
glutamate transporters 171. Other supporting evidence for the use of minocycline as a 
neuroprotective agent comes from its antioxidant properties, suppression of 
chemokines and their receptors, inhibition of T-cell migration into the CNS, protection 
of mitochondria, and promotion of anti-apoptotic and suppression of pro-apoptotic 
pathways 157. In the present study, the group treated with minocycline showed no 
evidence of improvement in sensory function at the follow-up test conducted during the 
course of chemotherapy treatment. Some measures such as pegboard completion 
time by the dominant hand suggest significant improvement in patients co-treated with 
minocycline and bortezomib compared to their initial tests, however this difference was 
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not significantly different from the bortezomib-treated patients and most likely 
represents a training effect. Thus, we failed to see reliable differences following 
minocycline that would suggest neuroprotective effects. Even if improvement had been 
observed, no conclusion could be made due to the lack of effect seen in the placebo 
group. 
        Given the clinical importance of this study in evaluating the potential application 
of minocycline in bortezomib-induced neuropathic pain, it was decided to consult the 
University of Texas MD Anderson Department of Biostatistics for a more formal 
analysis capable of adjusting for the complexities present in the dataset. For a 
description of the methods and findings of this analysis see Appendix B.  
        Limitations to this study were primarily related to the complexities of collecting 
prospective clinical data. The most significant limitation was the inability to obtain a 
baseline test on the vast majority of patients, which required that two separate 
analyses be performed. The first analysis had more restricted inclusion criteria, 
thereby limiting the sample size, while the second analysis included more patients, the 
majority of whom had already received chemotherapy at the initial test. Chemotherapy 
treatment prior to the initial test not only added a confounding factor, it also potentially 
diluted the effect of the chemotherapy on sensory function that could be observed at 
the follow-up test. Additionally, this subset of patients did not take minocycline at the 
start of chemotherapy. Pre-clinical studies indicate that the therapeutic time window for 
minocycline is limited to the initiation stage of neuropathic pain development 161. This 
could be a contributing factor for the lack of effect seen with minocycline. In addition, 
the majority of patients in this study received polymodal chemotherapy: bortezomib, in 
combination with lenalidomide, thalidomide, cyclophosphamide, and/or 
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dexamethasone. Administration of polymodal therapy likely impacts the development 
of neuropathy, and research suggests that bortezomib in combination with thalidomide 
or the related analog, lenalidomide, produces lower rates of neuropathy, perhaps due 
to anti-inflammatory effects of these drugs 172. Patients also received their follow-up 
testing at a large range of doses, which introduced additional variability.  
     Furthermore, the primary end point of the study was touch detection at the fingertip 
site. For this test, von Frey filaments of different forces were applied in an up/down 
fashion and the subject indicated when the stimulus was perceived. The recorded 
threshold was the force that the subject was able to detect three separate times. The 
filaments increase in force logarithmically (instead of linearly), which dramatically 
increases the probability that the subject detects the next heaviest filament and may 
underestimate potential differences. A lack of significance of the primary endpoint 
provoked the early closure of this study, which also limited the sample size.  
     Given the limitations inherent in the study, future clinical trials investigating the 
efficacy of minocycline in preventing bortezomib-induced neuropathy should ensure 
that all patients received a baseline test and begin the study medication prior to 
induction of chemotherapy. Patients should also be stratified based on the presence of 
baseline sensory deficits to ensure that treatment and control groups are balanced and 
display similar sensory thresholds at baseline. Quantitative sensory testing should be 
performed on the feet in addition to the hands, given that symptoms of bortezomib-
induced neuropathy predominate in the lower distal extremities. As mentioned, follow-
up testing in this study was performed approximately ten weeks after the initial testing, 
meaning that the majority of patients had not yet completed their fourth cycle of 
bortezomib. Given that sensory neuropathy increases with cumulative dose of 
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chemotherapy, quantitative testing in future studies should be performed at higher 
cumulative doses chemotherapy, which would allow testing of sensory thresholds at 
the peak of patient complaints of neuropathy. Lastly, given the potentially promising 
effect of minocycline in preventing bortezomib-induced patient reports of tingling and 
numbness, future studies should focus on patient-reported outcomes. Symptom quality 
as well as distribution on the body would be important aspects to consider. 
        In summary, this was a preliminary analysis performed on quantitative sensory 
data from a double-blinded randomized placebo/controlled study to evaluate the 
efficacy of minocycline in the prevention of bortezomib-induced neuropathy. Co-
administration of minocycline with bortezomib decreased patient reports of tingling and 
numbness, although statistical significance was not achieved. However, patients co-
treated with bortezomib and placebo did not experience sensory deficits as measured 
by QST compared to initial tests. In addition, co-administration of minocycline and 
bortezomib, did not produce measurable improvements as compared to placebo in 
sensory thresholds. Thus, the hypothesis that oral minocycline co-administered with 
the chemotherapeutic agent, bortezomib, would prevent sensory neuropathy induced 
by bortezomib and decrease patient-reported outcomes of neuropathy was only 
partially supported with a non-significant decrease of tingling and numbness in 
minocycline-treated MM patients after bortezomib. The dearth of patients with a 
baseline, inconsistencies in the time course that the study drug was administered, the 
use of different regimens of polymodal chemotherapy and variations in the dose at 
which the follow-up test was conducted are all inherent flaws with the dataset. The 
previous success of minocycline as a neuroprotective agent in clinical and pre-clinical 
studies as well as its potential to decrease patient reports of neuropathy in the above 
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study indicates that this drug may indeed have an effect in CIPN. The effect of 
minocycline on CIPN warrants further investigation in a more carefully controlled 
prospective trial. 
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4. Overall Discussion and Future Directions 
         Along with surgery and radiation, chemotherapy is the treatment of choice for 
cancer. According to the Center for Disease Control, the number of patients in the 
United States receiving chemotherapy is 650,000 annually. During and after their 
treatment, many of these patients will develop CIPN, a serious side effect that affects 
proper sensory function interfering with daily living and treatment administration. The 
studies that are the subject of this thesis focus on the subset of cancer patients 
diagnosed with MM prior to and following treatment with the proteasome inhibitor, 
bortezomib. The goals of these studies were to quantify changes in sensory thresholds 
induced by underlying disease processes of cancer as well as to assess the efficacy of 
minocycline in preventing sensory neuropathy.  
         Given that approximately 10% of MM patients present with overt clinical 
neuropathy prior to receiving chemotherapy, it was hypothesized that greater numbers 
of MM patients exhibit quantifiable changes in sensory thresholds prior to receiving 
chemotherapy. To investigate this hypothesis MM patients underwent QST prior to 
having received any chemotherapy treatment and were compared to healthy 
volunteers. This is the first study conducted on treatment-naïve MM patients to 
quantitatively describe changes in sensory thresholds that are suggestive of 
impairments in Aβ-, Aδ-, and C-fiber function. In addition, failure to detect small-sized 
bumps in a fine tactile discrimination task was correlated with a decreased density of 
touch receptors, MCs, in the skin of MM patients. Thus, prior to treatment with 
chemotherapy, MM patients already exhibit impairments in mechanosensation, 
thermal sensation, and sensorimotor tasks and decreased densities of touch 
receptors. These findings are most likely indicative of the direct or indirect effects of 
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the MM disease, which have been reviewed in the literature 173,174. It has been 
suggested that the presence of subclinical sensory deficits in patients predisposes 
them to develop treatment-emergent peripheral neuropathy. If this is the case, those 
patients with disease-related neuropathy may require smaller initial doses of 
bortezomib or increased monitoring throughout treatment. Future studies should aim to 
establish whether there is a connection between subclinical sensory deficits and 
treatment-emergent neuropathy. Specifically, it would be interesting to evaluate 
whether those patients with subclinical deficits develop treatment-emergent 
neuropathy sooner and whether the manifestation is more severe than those who do 
not have subclinical deficits. If a clear link is established, this will be a patient 
population who may benefit from the application of preventative therapies.  
        The second hypothesis explored was that MM patients treated with bortezomib 
show chemotherapy-induced deficits in sensory function that can be detected by QST 
and reversed with the administration of the preventive therapy, tetracycline antibiotic, 
minocycline. Killing cancer by reversibly inhibiting proteasomes and facilitating cell 
death by allowing the build-up of toxic levels of proteins seemed like an unlikely cancer 
therapy until it proved efficacious and was approved for use in multiple myeloma 
patients under the trade name Velcade® (bortezomib) 82. While quite effective at 
treating MM, bortezomib does not only selectively destroy cancer cells, but also preys 
on non-cancer cells. The somatosensory system is particularly vulnerable to the 
effects of bortezomib via its ability induce changes in the DRG, which is unprotected 
by the blood-brain barrier. Injury of the somatosensory system by bortezomib is a 
toxicity causing neuropathic pain to develop in a glove-and-stocking distribution on 
patients and frequently results in dose-reduction or cessation of treatment. The utility 
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of bortezomib as a treatment for multiple myeloma is restricted by its damage to the 
peripheral nervous system (PNS). Optimization of bortezomib treatment will include 
reducing or eliminating the damage to the PNS, thereby eliminating the symptoms of 
neuropathic pain in patients.  
        In the second study, we explored the presence of bortezomib-induced deficits 
and described the first double blind, placebo-controlled study investigating minocycline 
as preventative agent for bortezomib-induced neuropathy. A preliminary analysis of 
QST data from MM patients co-administered placebo and bortezomib showed no 
detectable decline in sensory function of the placebo group. However, bortezomib did 
increase patient reports of tingling and numbness consistent with neuropathy in the 
placebo group. Although statistical significance was not achieved, it appeared that 
minocycline may have prevented increases in patient-reported tingling. Difficulties 
inherent in the collection of prospective clinical data that resulted in the presence of 
confounding factors may have disguised any positive effect of minocycline, making it 
difficult to discount the potential therapeutic value of this drug. Therefore, the 
neuroprotective effects of minocycline observed in pre-clinical and clinical studies 
warrant further investigation in a more thoroughly conducted study. 
        Despite much investigation, chemotherapy-induced peripheral neuropathy is still 
a problem pervasive in cancer patients treated with chemotherapy, few novel agents 
have proved effective in pre-clinical studies and of these, no single agent has proved 
effective in clinical trials. The failure to develop effective therapies stems from our lack 
of understanding of mechanisms underlying bortezomib-induced peripheral 
neuropathy and more broadly, CIPN. Understanding the changes chemotherapy 
induces in receptor and protein expression in neurons associated with symptoms of 
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neuropathy will inform the development of drugs aimed to protect these targets.  It is 
this gap of knowledge that will most adequately be addressed with animal studies. 
Several correlate animal studies will be described in Appendix C as a supplement to 
the clinical data previously discussed.  
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5. Appendices 
5.1. Appendix A: Central Processing of Pain 
        The spinal cord and brain comprise the CNS. Primary afferent sensory neurons of 
the peripheral nervous system project axons to synapse in the spinal cord (Figure 25). 
The spinal cord is composed of central gray matter (containing cell bodies of central 
neurons) surrounded by white matter (containing afferent and efferent axons). The 
dorsal portion of the gray matter receives sensory afferent input from the periphery, 
and the ventral gray sends efferent motor information to the periphery. The central 
gray matter is divided into eight distinct areas called laminae I- VIII (Figure 25). 
Nociceptive primary afferents (Aδ- and C-fibers) project to secondary neurons located 
in laminae I and II of the spinal dorsal horn, which project to the brain in the 
spinothalamic tract. In addition, to these nociceptive-specific neurons, wide-dynamic-
range neurons (WDRs) are also present in lamina I and receive information about 
mechanical stimuli (both nociceptive and non-nociceptive) 13. WDRs are also located 
in lamina V and project to the brainstem and thalamus.  WDRs in lamina V have 
dendrites that extend into laminae I and II and make direct contacts with C-fibers. They 
also receive indirect information from C-fibers via interneurons and monosynaptic input 
from Aβ- and Aδ-fibers 13. Nociceptive visceral afferents also terminate in lamina V. 
Non-nociceptive Aβ-fibers predominately terminate in laminae III and IV and have 
topographically organized receptive fields. Finally, some neurons in laminae VII and 
VIII may receive ipsilateral and contralateral polysynaptic nociceptive input and 
contribute to the sensation of diffuse pain. 
         When stimulated, primary afferent nociceptors release excitatory (glutamate) and 
peptide neurotransmitters that bind to their respective receptors on central neurons. 
106 
 
Glutamate release from Aδ- and C-fibers produces fast depolarization and action 
potentials in dorsal horn neurons 12,175. Peptide neurotransmitters, such as substance 
P, are also released by peptidergic C-fibers and produce a slower depolarization than 
glutamate in spinal dorsal horn neurons 13. Peptidergic and non-peptidergic 
transmitters have different properties and may contribute to different aspects of 
synaptic transmission. Non-peptidergic transmitters (e.g.: glutamate) have a more 
limited range of action than peptide transmitters due to their reuptake by nerve 
terminals or glial cells 13. The lack of a reuptake mechanism for peptide transmitters 
means that they will stay longer in the synaptic cleft and activate a larger area of 
secondary neurons in the spinal cord. Peptidergic transmitters also work 
synergistically with non-peptidergic transmitters by perpetuating their effects. 
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Figure 25  Primary Afferent Neuron Synapses in Dorsal Spinal Cord 
Illustration of a hemisected spinal cord with gray matter surrounded by white matter. 
Primary afferent fibers in the skin have cell bodies located in the dorsal root ganglion 
(DRG) and synapse in an organized fashion on different laminae in the spinal cord. 
Unmyelinated C-fibers (black) synapse in laminae II of the spinal dorsal horn on 
secondary order nociceptors (red) and wide dynamic range neurons (green). Thinly 
myelinated Aδ-fibers (orange) project to lamina I on nociceptive secondary neurons. 
Large myelinated Aβ-fibers synapse predominately on WDR neurons in lamina V of 
the spinal dorsal horn. 
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        When an individual sustains a localized tissue injury, that area becomes and 
remains tender long after the initial damage. Subsequent stimulation of that area 
induces pain even if the magnitude is much lower than the initial damaging stimulus. 
This is called hyperalgesia and is caused by the sensitization of nociceptors. 
Nociceptors are sensitized when the threshold for activation is lowered; damaged cells 
and tissues release substances such as prostaglandin, substance P, acetylcholine, 
bradykinin, serotonin and leukotriene, which sensitize nociceptors 43. Although primary 
afferents receive sensory information, they are also capable of releasing substances 
(e.g., substance P and cGRP) synthesized in the cell body in response to injury 176. 
These chemical mediators cause vasodilation and lead to inflammation and the 
release of other substances that sensitize nearby primary afferents, in a process 
termed axon reflex 176,177. Activation of N-methyl-D-aspartate (NMDA) channels by 
glutamate underlies “wind-up” and is one of the mechanisms that produces central 
sensitization 56.  Wind-up occurs due to the persistent firing of C-fibers after serious 
injury. Central sensitization occurs when input from primary afferents provokes spinal 
dorsal horn neurons to change expression of certain genes, thereby causing an 
intrinsic change in firing patterns and hyperexcitabillity 56. This can lead to the 
perception of pain in the absence of stimulation. 
        Spinal dorsal horn neurons relay pain information to the brain in five ascending 
pathways: spinothalamic, spinoreticular, spinomesencephalic, cervicothalamic, and 
spinohypothalamic 13. The spinothalamic pathway is the major pain pathway, which 
carries axons of contralateral spinal dorsal horn neurons from laminae I, V, VI, and VII 
in the anterolateral white matter to the thalamus for further processing. Descending 
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inhibitory pathways modulate transmission of pain by inhibiting spinal dorsal horn 
neurons and thereby evoking analgesia 178. 
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Figure 26 Central Pain Processing 
Nociceptive primary afferent neurons (1) relay the sensation of pain to the central 
nervous system by synapsing on second order spinal dorsal horn neurons (2). Spinal 
dorsal horn neurons decussate and ascend in the spinothalamic tract located in the 
contralateral anteriorlateral funiculus (3) to the brain (4). 
   
Reprinted from American Association of Critical Care Nurses (ACCN), Renn C and 
Dorsey S. Physiology and Processing of Pain: A Review. Copyright 2005, reprinted 
with permission from Wolters Kluwer Health.  
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5.2. Appendix B: Additional Statistical Analysis for Chapter 3 
         Chapter 3 describes a preliminary analysis of the quantitative sensory data from 
a phase II study of minocycline vs. placebo to prevent treatment-induced neuropathy 
in multiple myeloma patients. Given the limitations of the analysis performed, the 
Department of Biostatistics was consulted and asked to perform a separate analysis in 
order to account for the effect of multiple independent variables on the dependent 
variable (quantitative sensory measure). 
        The study design was explained at length, and the statistician was provided with 
a spreadsheet populated with de-identified patient data. Sixty of 72 patients received 
at least two tests and were included in the analysis. Patients with only one QST were 
excluded. The following analysis included more patients than Analysis #2 in Chapter 3 
because all patients with two tests were included regardless of whether the initial test 
was performed at less than 13 mg of chemotherapy. The same measures as above 
were analyzed for the fingertip, thenar eminence and forearm. The dependent variable 
in this analysis was either analyzed using the value at the follow-up QST at the 
maximum cumulative dose of bortezomib or converted into a difference score by 
subtracting the value recorded at the lowest cumulative dose of bortezomib (the initial 
test) from the value at the highest cumulative dose of bortezomib (the follow-up test).  
Backward stepwise regression approach was used for variable selection of 
multivariable analyses. The outcome variable (the dependent variable) was either the 
follow-up QST value at the highest cumulative dose or the difference score. The input 
variables (independent variables) were study drug (minocycline or placebo), whether 
study drug was administered prior to bortezomib treatment (yes or no), myeloma stage 
(I, II, or III) and cumulative dose in milligrams. P-values less than 0.05 were 
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considered statistically significant and all tests were two-sided. Due to the exploratory 
nature of this study, no adjustment of multiple tests was performed. All analyses were 
performed using SAS 9.3 (SAS Institute Inc., Cary NC).  
        Adjusting for cumulative dose, whether the study drug was administered prior to 
bortezomib, and multiple myeloma stage, minocycline treatment was significantly 
associated with a higher temperature of heat pain detection at the fingertip (P=0.04) 
and thenar eminence (P=0.01), and lower temperatures of cool detection at the 
fingertip (P=0.04), thenar eminence (P=0.03), and volar forearm (P=0.04). Using the 
difference score for QST measurements and adjusting for whether the study drug was 
administered prior to chemotherapy and the stage, minocycline was only associated 
with a decrease in the temperature of cool detection at the forearm (P=0.02) 
        Limitations of this analysis include the fact that adjustments for cumulative dose 
and whether the study drug was administered prior to chemotherapy were performed 
for the total group of patients (N=60) analyzed. However, these adjustments should 
have been made separately for the minocycline versus placebo group because it 
would be expected that the administration of treatment prior to bortezomib would only 
be important for the minocycline group if there were a time-dependent effect of the 
drug, but not for placebo. Adjustments for cumulative dose should also have been 
adjusted for separately in minocycline vs. placebo groups because if minocycline 
impacts QST then it may change a dose-dependent effect of bortezomib on sensory 
function.  
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5.3. Appendix C: Related Preclinical Studies 
        To complement the clinical studies presented in this thesis, several pre-clinical 
studies in animal studies were performed in animal models of chemotherapy-induced 
neuropathy. Two additional frontline chemotherapeutic agents that commonly cause 
neuropathy were investigated in the following studies.       
       Prior to investigating peripheral innervation in patients using in vivo confocal 
microscopy as explained in Chapter 2, biopsies were collected at skin sites that 
depicted symptoms of neuropathy. Skin biopsies from patients treated with 
chemotherapy showed reduced numbers of nerve fibers compared to biopsies of 
healthy controls. Similar quantifications were performed in rodents treated with 
chemotherapy. 
        Aδ- and C-fibers are subtypes of nerve fibers that originate in the dermis layer of 
skin and usually cross the dermal-epidermal junction to terminate in the epidermis as 
free nerve endings, called intraepidermal nerve fibers (IENFs) (Figure 27). A hallmark 
of many small fiber peripheral neuropathies is a decrease in the density of IENFs 179. 
Decreases in IENF density are present in patients with symptomatic bortezomib-
induced peripheral neuropathy 89 and in rodent models of paclitaxel- and oxaliplatin-
induced neuropathic pain 162,163. Loss of IENFs seems to approximately correlate with 
symptoms of neuropathy, but it is unclear whether or not their loss is responsible for 
the hypersensitivity, pain, dysesthesias or paresthesias felt by patients. If the loss of 
IENFs underlies symptoms, the question becomes how missing fibers are able to 
produce the uncomfortable symptoms of pain and tingling and why they instead do not 
produce numbness. The release of cytokines from injured fibers may be driving 
symptoms of neuropathy. Since the loss of IENFs may contribute to symptoms of 
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neuropathy, treatments that are able to block development of neuropathy might also 
be expected to spare nerve fibers. Based on a recently-published study, monocyte 
chemoattractant protein-1 (MCP-1) and its chemokine receptor 2 (CCR2) are involved 
in the induction and maintenance of paclitaxel-induced neuropathic pain. Knockdown 
of CCR2 with intrathecal siRNA attenuates behavioral sensitivity of rodents after 
paclitaxel treatment and has IENF densities similar to vehicle-treated animals (Figure 
28) 179. 
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Figure 27 Intraepidermal Nerve Fibers in Rodent Skin 
In red, IENFs labeled with protein gene product 9.5 (PGP 9.5) and in green, collagen 
delineating the dermal-epidermal junction in the foot pad of a normal rat. 
 
  
  
 
Figure 28 Blockade of MCP
(A) Representative images of IENFs 
treated with combinations of nonspecific control peptide IgG (NS/IgG
IgG. Co-treatment with anti
and paclitaxel-treated animals had significantly lowe
quantification of IENFs in each treatment condition. 
 
Reprinted from Journal of Pain 14(10), Zhang H, Boyette
Y, Yoon SY, Walters ET, Dougherty PM, Induction of monocyte chemoattractant 
protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to 
paclitaxel-induced peripheral neur
from Elsevier.  
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(red) in the glabrous hindpaw skin of the rats 
-MCP-1 and paclitaxel spared IENFs while control peptide 
r densities of IENFs. (B)
 
-Davis JA, Kosturakis AK, Li 
opathy. Copyright 2013, reprinted with permission 
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        Quantification of IENFs is performed on slices of skin tissue co-stained with 
protein gene product 9.5 (PGP 9.5) expressed in the cytoplasm of neurons and 
collagen. Collagen delineates the dermal epidermal junction and restricts quantification 
to epidermal fibers. PGP 9.5 is believed to be a pan neuronal marker for IENFs. Other 
markers such as calcitonin gene-related peptide (CGRP) are thought to label the 
subset of PGP 9.5 fibers expressing CGRP. Figure 29 shows double staining of PGP 
9.5 and CGRP markers and a perfect co-localization of CGRP fibers with PGP. Further 
experiments, however, show CGRP positive fibers that lack PGP 9.5 staining at 
concentrations normally used for quantification (1:500 and 1:400, respectively) (Figure 
30). This provoked the question: is PGP 9.5 really a pan neuronal marker? The 
implication of this is that PGP 9.5 may not be a reliable marker for quantifying 
neuropathy if is not a pan neuronal marker. Further studies are needed to determine if 
there are large populations of nerves unlabeled by PGP 9.5.  
 
 
 
 
 
  
Figure 29 PGP9.5 and C
CGRP (green) IENFs co-localize (yellow)
hindpaw footpad. 
 
 
 
 
 
Figure 30 Some CGRP Positive Fibers Do Not Appear to Express PGP9.5 
CGRP-expressing fibers in green
positive fibers (solid arrow) do not c
to the location where the CGRP positive fiber should have been present
 
 
 
PGP 9.5 
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GRP are Co-Localized in Intraepidemal Nerve F
 with PGP 9.5 (red) in the epidermis of rodent 
 and PGP 9.5-expressing fibers in red. Some CGRP 
o-localize with PGP 9.5. The unfilled arrow points 
 CGRP PGP 9.5/CGRP
ibers 
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       As described in the discussion of Chapter 2, various cytokines, which include 
chemokines, are implicated in various inflammatory and pain states 180,181. The 
following study was performed in pre-clinical models to investigate the contribution of 
the chemokine, monocyte chemoattractant protein 1 (MCP-1) and its cognate receptor, 
CCR2, in several inflammatory and neuropathic pain models. To investigate the role of 
CCR2 in pain, the painful-behavioral phenotypes of CCR2 knockout (CCR2-KO) 
mouse were compared to those of wildtype mice. Intraplantar injection of formalin and 
complete Freund’s adjuvant (CFA) served as acute and chronic inflammatory pain 
models, respectively. The neuropathic pain models used were spared nerve injury 
(SNI) and chemotherapy (paclitaxel and oxaliplatin).  
        1% Formalin (10 µl) was unilaterally injected to the hindpaw and licking time was 
measured. CCR2-KO mice showed no difference in phase 1 (0-10 minutes) or phase 2 
(10-45 minutes) of formalin-induced spontaneous pain (Figure 31).  
        Complete Freunds Adjuvant (CFA) was injected unilaterally into the hindpaws of 
wildtype and CCR2-KO mice and mechanical testing was performed on days 1, 3, 7, 
15, 20, and 27 after injection. CCR2-KO mice and wildtype mice showed similar 
mechanical allodynia after intraplantar CFA that resolved by Day 27 (Figure 32).  
         Sural and common peroneal branches of left sciatic nerve were ligated and 
transected as described 182. CCR2-KO mice showed similar withdrawal thresholds as 
sham mice and significantly less mechanical sensitivity compared to wildtype mice on 
post-operative days 7 and 14 (Figure 33).  
         Paclitaxel (2 mg/kg) was injected intraperitoneally on days 1, 3, 5, 7. Mechanical 
withdrawal thresholds were tested at Days 7, 14, and 21. CCR2-KO mice treated with 
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paclitaxel showed less mechanical hypersensitivity compared with wildtype mice 
(Figure 34).  
        Oxaliplatin (3mg/kg) was injected intraperitoneally every day for 5 days. CCR2-
KO mice and wildtype mice showed similar decreases in withdrawal thresholds after 
oxaliplatin injection (Figure 35). 
        Taken together, these data suggest that CCR2 contributes to neuropathic, but not 
inflammatory pain. Furthermore, CCR2 is involved in neuropathic pain induced by 
spared nerve injury and paclitaxel, but not oxaliplatin. Further studies could investigate 
the reasons CCR2 is involved in paclitaxel, but not oxaliplatin-induced neuropathy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 31 CCR2-KO Mice Showed No Difference in Formalin
Spontaneous Pain 
Duration of licking time in both phase 1 and phase 2 is simi
CCR2-KO mice after intrap
 
 
 
 
 
 
 
Figure 32 CCR2-KO Mice Showed No Difference in CFA
CCR2-KO mice showed similar mechanical withdrawal thresholds after intraplantar 
CFA injection. 
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Figure 33 CCR2-KO Mice Showed Less Mechanical Hypersensitivity after Spared 
Nerve Injury 
Mechanical allodynia was significantly reduced in CCR2-KO mice after spared nerve 
injury. * P< 0.05, Two-Way ANOVA with Tukey’s post hoc test. 
 
 
 
Figure 34 CCR2- KO Mice Showed Less Mechanical Hypersensitivity after 
Paclitaxel Treatment 
*P<0.05, Multiple t-test 
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Figure 35 CCR2-KO Mice Showed No Reduction in Oxaliplatin-Induced 
Mechanical Hypersensitivity 
*P< 0.01, Saline CCR2 vs. Oxaliplatin CCR2-KO, Two-Way ANOVA with Tukey’s post 
hoc test. 
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